The Classification of Drugs and Drug Receptors in Isolated Tissues

TERRY P. KENAKIN

Department of Pharmacology, The Wellcome Research Laboratories, Burroughs Wellcome Co., Research Triangle Park, North Carolina

I. Introduction

The major premise of this review is that isolated tissues can be used effectively to obtain information about drugs and drug receptors which transcends species and function. This information, in turn, should be valuable in the definition of drug action and the design of more effective therapeutic agents for man. In this context, the bias of this paper will be pharmacological in that receptors will be used to gain information about drugs rather than the more physiological bias of drugs.
used to gain information about receptors. This bias is reflected in the still very timely statement made by Buchheim 135 years ago.

The information about drugs obtained from isolated tissues becomes useful for classification purposes which, it is hoped, leads to general statements about structure and activity. The essentially circular nature of the drug and drug receptor classification process should be kept in mind. New receptor types or subtypes are discovered only after the discovery of new selective drugs. Then new drugs are classified by their interactions with these new receptors. It will be another bias of this paper that drugs probably have more than one activity and are selective rather than specific. This is a parsimonious view in receptor terms since it seeks to explain selectivity or lack of it in terms of multiple properties of drugs rather than multiple subtypes of receptors.

The use of isolated tissues to classify drugs has its drawbacks in the dependence of this process on previous classifications. For example, in the early subclassification process for \( \beta \)-adrenoceptors, the guinea pig trachea was classified as containing \( \beta_2 \)-adrenoceptors and tracheal-selective \( \beta \)-agonists were accorded the corresponding label of \( \beta_2 \)-adrenoceptor selective. The advent of data which suggest that trachea contains both \( \beta_1 \)- and \( \beta_2 \)-adrenoceptors necessarily must bring into question the original \( \beta_2 \)-selective classification of these agonists. Unfortunately, there is usually a time lag between the classification of the drugs and the reclassification of the tissue and the possibly erroneously classified agonists may be used to classify other tissues incorrectly. The potential for a baroque web of conflicting classification data for tissues and drugs in this process is obvious. Some of these problems may be avoided if tissue selectivity is not assumed to be receptor selectivity.

In this paper, an attempt will be made to review some of the null methods available to measure the strictly drug-receptor-related parameters of affinity and intrinsic efficacy, and more importantly, the internal checks in these methods to detect receptor heterogeneity. The major advantage of isolated tissue experimentation is the potential to directly measure relative efficacy of agonists (235). In this regard, this technique holds advantages over biochemical binding techniques which primarily yield estimates of affinity.

**A. Isolated Tissue and Binding Studies**

Currently there is controversy over the significance of the similarities and differences between binding and isolated tissue data. Unfortunately, there are all too few laboratories that do both techniques and critically compare the results (169). There are studies that show estimates of affinity of drugs in isolated tissue and binding studies to be equivalent for a variety of receptors including muscarinic receptors (52, 53, 235, 612, 712), \( \beta \)-adrenoceptors (458, 459, 699), and \( \alpha \)-adrenoceptors (320, 606). However, differences between isolated tissue and binding studies have been noted as well. For example, the binding \( K_d \) values for some \( \beta_2 \)-adrenoceptor agonists do not correlate well with the relative potencies of these drugs in isolated tissues (413). Similarly, although the selectivities of antagonists for \( \beta_1 \)- and \( \beta_2 \)-adrenoceptors as measured in binding and isolated tissue studies correlate well, the correlation for agonists is poor (71). This is most likely because pharmacological agonist activity depends upon affinity and intrinsic efficacy, the latter parameter being essentially inaccessible in binding studies. Agonist activity in broken cell preparations can be measured (for example, \( \beta \)-adrenoceptor agonists on adenyl cyclase) but the lack of amplification which is present in tissues makes detection of all but quite powerful agonists not possible biochemically. The amplification processes inherent in the stimulus-response mechanisms of isolated tissues make isolated tissues much more suitable for prediction of agonist activity in vivo.

Ingenious methods have been applied in binding studies to differentiate between agonists and antagonists which theoretically could lead to quantification of relative efficacy biochemically. Thus the differential effects of sodium ion on opiate receptor binding (516), the differences in free energy of binding (691) or effects of GTP and GpNHpp (439, 699) on \( \beta \)-adrenoceptor binding and the differential effects of GABA on benzodiazepine binding (586) all offer unique approaches to this problem.

One apparent advantage binding studies have over isolated tissue studies is the ability to measure receptor density. Care must be taken, however, in interpreting these estimates of receptor density. The difficulty comes in predicting the relevance of the actual proportions of heterogeneous receptor populations to pharmacological responses; i.e., will a ratio of 80:20 \( \beta_1 \)- to \( \beta_2 \)-adrenoceptors in a tissue translate to a more \( \beta_1 \)- than \( \beta_2 \)-adrenoceptor profile in terms of pharmacological responses? Actually the probability of direct correspondence is low in view of the coupling processes involved between receptor activation and tissue response. For example, Homburger and coworkers (325) have noted that even though \( \beta_1 \)- and \( \beta_2 \)-adrenoceptors coexist on single \( C_9 \) cloned glioma cells, the coupling of the two receptors to adenyl cyclase is not of equal efficiency. The effects of receptors coupling on tissue responsiveness can be demonstrated in ontogenetic studies. For example, although \( \beta \)-adrenoceptors can be detected in fetal mouse hearts in binding studies, no responses to isoprotroterol can be elicited until later in the cycle of tissue development (709). A study by Hoffmann and coworkers (318) has shown that although the state of oestrous in female rats greatly affected the relative number of \( \alpha \)-adrenoceptor and \( \beta \)-adrenoceptor subtypes, the changes in pharmacological responses did not coincide with the receptor changes measured in the binding studies. In view of the influence of receptor coupling on drug responses, a theoretically more complete approach to the study of the mechanism of action
of drugs would incorporate both binding and isolated tissue studies.

II. Factors in the Choice of Isolated Tissues

There are many factors to consider when choosing an isolated tissue system for pharmacological experiments. Numerous techniques have been identified to detect and eliminate obstacles to the attainment of the primary requisites for isolated tissues, namely uniformity and stability.

A. Animals

The use of age-, weight-, and strain-matched animals should reduce the incidence of variation (246). For certain types of experiments, special animals such as the spontaneously hypertensive rat (479) or cardiomyopathic hamsters (619) can be utilized. For other procedures, surgically altered animals can yield tissues that approximate the effects of pathological conditions in various organs observed in man. Thus, cardiac tissues from animals in cardiac failure can be obtained from cats which chronically obstructed pulmonary arteries (248, 251) or rats with aortic insufficiency, aortocaval fistulae, or aortic stenosis (211). For certain tissues, such as myometrium, the hormonal state of the animal (oestrous, pre- oestrous, etc.) also is important (88, 91, 181, 542, 455).

B. Preservation of Tissue Viability

Historically, pioneering work by many researchers such as Tyrode (645) and Krebs (398, 399) has led to the definition of nutrient solutions capable of preserving isolated tissues in a viable state. Different tissues require a different milieu of ions and nutrients. Changes in ionic content and composition can affect tissue reactivity and base-line activity. For example, high osmotic pressure depresses cardiac pacemaker activity (393, 595). Changes in levels of potassium ion (252, 480, 584, 585) or magnesium ion (9) can greatly modify isolated blood vessel tone and reactivity to agonists. Specific changes in ionic composition can eliminate spontaneous activity in some tissues and allow stable steady-state responses to agonists. For example, the reduction of calcium ion (30) or the elimination and graded readdition of calcium ion (375) to de Jalon solution bathing rat uterus produces a quiescent or regularly contracting tissue suitable for bioassay.

Adequate delivery of oxygen to the tissue is another prime consideration. The basal activity of smooth muscle (122, 180) and cardiac muscle (82) can be affected by changes in the partial pressure of oxygen in the organ bath (Po2). For example, the contractile responsiveness of arterial smooth muscle decreases with decreasing Po2, the effects being more pronounced for thick- rather than thin-walled vessels and also for high levels of contractile stimulus (122, 180). From A. V. Hill's classic equation describing diffusion of soluble substances into muscle (315), as modified by Chang and Detar (122), it can be seen that complete delivery of dissolved oxygen to the cells of a given isolated tissue depends upon the partial pressure of oxygen in the organ bath medium (Po2 bath), the thickness of the tissue, and the rate of oxygen consumption of the tissue (Vo2). Thus, for a flat isolated tissue preparation (122):

\[
\frac{Po2_{(wall)}}{Po2_{(bath)}} = 1 - \frac{Vo2}{120SD} (T \times X^2)
\]

where \(Po2_{(wall)}\) is the partial pressure of oxygen in the tissue wall (torr) at depth \(X\) (distance from surface toward center of the tissue, cm). Wall thickness is \(T\) (cm), \(S\) is the solubility coefficient of oxygen within the wall (ml·cm⁻³·760 torr⁻¹), and \(D\) is the diffusion coefficient of oxygen within the wall (cm²·min⁻¹). The oxygen consumption, \(Vo2\), is in ml·cm⁻³·h⁻¹. With Hill's original equation, the so-called "critical" thickness or diameter of a tissue can be calculated beyond which a hypoxic core of cells would be expected (82, 122). However, calculations of this type assume homogeneous oxygen consumption and diffusion into the tissue, estimations which probably are oversimplifications making such predictions only rough guidelines. For example, the oxygen consumption of cardiac muscle has been shown to vary greatly with contractile state (82), or age of animal (157). The dependence of critical thickness upon contractile state makes it a possibility that an adequately oxygenated tissue in the resting state may become hypoxic during exposure to an agonist which increases contractile function. If, in turn, the functional contractility of the tissue is dependent upon viable cells (i.e., little contractile reserve) then the magnitude of the responses to the agonist may be dependent upon the Po2 in the organ bath.

The temperature of the medium bathing the isolated tissue is another consideration. For example, cooling to 32°C reduces spontaneous activity in rat uterus (30). Cardiac tissue has been shown to provide more stable basal activity and responsiveness to agonists at temperatures below 37°C (81, 82).

The pH of the bathing solution can affect basal activity and responses of isolated tissues to drugs. For example, the spontaneous rate and force of rabbit atria (333, 671), dog atria (561), perfused hearts of guinea pigs (449), and rat atria (392) decrease with lowered bath pH. Alternati- vely, deviations in pH may influence ionization of drugs or charged chemical groups on receptors thereby chang- ing the moieties which interact to produce response. The responses of rabbit atria to histamine are stable when the pH of the bathing medium is kept between 7 and 7.6. However, at pH <7, the responses to histamine become depressed (333). Similarly, the responses of smooth mus- cles to histamine are stable in a pH range of 7.0 to 8.3 but decline sharply at pH <7 (543, 544). The responses of rat atria to norepinephrine are increased during al- kalosis and decreased by acidosis (116) while the re-
sponses of rat uterus to oxytocin are potentiated by acetic acid (57).

In general, there is much evidence to show that the ionic composition, \( \text{PO}_2 \), pH, and temperature of the bathing media for isolated tissues can affect viability and responsiveness.

**C. Some Isolated Tissues from Animals and Man**

The ideal experimental conditions for various experimental preparations have been reported in the literature and the subtle variations in experimental conditions that work best for particular isolated tissues can be obtained from papers describing pharmacological procedures with these tissues. A list of some of the isolated tissue preparations used for the study of receptors for neurotransmitters, autacoids, and hormones is given in table 1. This list excludes receptors for various biologically active substances such as leukotrienes, thromboxanes, prostaglandins, calcium ions (channels), and peptides which are discussed in specialized reviews and monographs. Also not shown in this table are receptor subclassifications (i.e. \( \alpha_1 \)- and \( \alpha_2 \)-adrenoceptors) since, for many tissues, the predominance of the receptor subtype was not clear at the time of writing. Also, for many of the putative receptor subclassifications, the pharmacological criteria for definition by selective agonists and antagonists have not yet been defined. Shown in table 1 are references to papers in which the conditions and method of preparation of the tissue for the specified receptor are described. Therefore, more than one reference may be given for the same tissue if different drug receptors are studied that require different experimental conditions. It should be noted that the references in table 1 are not necessarily historically accurate from the point of view of first describing the isolated tissue for pharmacological experimentation. This is because, in most cases, subsequent usage of the tissue preparation by other workers has led to modifications and improvements in the techniques. Therefore, examples of recent papers where authors have given methodological details and concentration-response curves to agonists are cited in the interest of enabling the reader to use the table as a reference to the isolated tissue preparations available.

There is a large body of experimental evidence to suggest that there is pharmacological correspondence between the drug receptors in animals and man. Obviously there are important ethical considerations in the testing of drugs in man but certain surgical procedures and the rapid post-mortem acquisition of biological tissue make possible the testing of drugs in human tissue in vitro. Some of the tissue preparations isolated from humans for the study of drugs are shown in table 2.

**D. Methods of Tissue Preparation**

The method of tissue preparation can be an important factor in pharmacological experiments. The wide range of sizes of vascular tissue requires a correspondingly wide

### Table 1

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Species</th>
<th>Tissue</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adenosine</td>
<td>Rat</td>
<td>Bladder</td>
<td>(102)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ileum</td>
<td>(49)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Portal vein</td>
<td>(583)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vas deferens</td>
<td>(130)</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Atria</td>
<td>(372)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trachea</td>
<td>(140, 141)</td>
<td></td>
</tr>
<tr>
<td>Rabbit</td>
<td>Ileum</td>
<td>(7, 225)</td>
<td></td>
</tr>
<tr>
<td>Cat</td>
<td>Coronary artery</td>
<td>(489)</td>
<td></td>
</tr>
<tr>
<td>Dog</td>
<td>Atria</td>
<td>(127)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Basilar artery</td>
<td>(469, 630)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Coronary artery</td>
<td>(650)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mesenteric artery</td>
<td>(650)</td>
<td></td>
</tr>
</tbody>
</table>

### Table 1

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Species</th>
<th>Tissue</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angiotensin</td>
<td>Rat</td>
<td>Aorta</td>
<td>(137)</td>
</tr>
<tr>
<td></td>
<td>Carotid artery</td>
<td>(138)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Colon</td>
<td>(531, 533)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jugular vein</td>
<td>(138)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mesenteric artery</td>
<td>(137)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stomach</td>
<td>(532)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vas deferens</td>
<td>(457)</td>
<td></td>
</tr>
<tr>
<td>Rabbit</td>
<td>Aorta</td>
<td>(532)</td>
<td></td>
</tr>
<tr>
<td>Cat</td>
<td>Coronary artery</td>
<td>(489)</td>
<td></td>
</tr>
<tr>
<td>Receptor</td>
<td>Species</td>
<td>Tissue</td>
<td>References</td>
</tr>
<tr>
<td>--------------</td>
<td>----------</td>
<td>---------------------------------</td>
<td>------------</td>
</tr>
<tr>
<td>β-Adrenergic</td>
<td>Rat</td>
<td>Adipose tissue</td>
<td>(206)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atria</td>
<td>(605)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coronary artery</td>
<td>(50)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jugular vein</td>
<td>(138)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Uterus</td>
<td>(205, 181)</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Atria</td>
<td>Extensor digitorum longus</td>
<td>(233)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trachea (104, 505)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vas deferens</td>
<td>(205)</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Aorta</td>
<td></td>
<td>(94, 194, 230, 505)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atria</td>
<td>(94, 505)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coronary artery</td>
<td>(171)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ear artery</td>
<td>(169)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Facial vein</td>
<td>(510)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Portal vein</td>
<td>(194)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Small intestine</td>
<td>(230)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stomach fundus</td>
<td>(94)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trachea</td>
<td>(94)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vena cava</td>
<td>(194)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vesicourethral muscle</td>
<td>(390)</td>
</tr>
<tr>
<td>Cat</td>
<td>Atria</td>
<td></td>
<td>(81)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coronary artery</td>
<td>(489)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Middle cerebral artery</td>
<td>(193)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Nictitating membrane</td>
<td>(670)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Papillary muscle</td>
<td>(363)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Trachea</td>
<td>(424)</td>
</tr>
<tr>
<td>Mouse</td>
<td>Spleen</td>
<td></td>
<td>(86)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coronary artery</td>
<td>(46, 86)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Skeletal muscle artery</td>
<td>(46)</td>
</tr>
<tr>
<td>Pig</td>
<td>Coronary</td>
<td></td>
<td>(50, 186, 351)</td>
</tr>
<tr>
<td>Bovine</td>
<td>Iris sphincter</td>
<td>(502)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trachea</td>
<td></td>
<td>(22)</td>
</tr>
<tr>
<td>Bradykinin</td>
<td>Rat</td>
<td>Uterus</td>
<td>(38)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Stomach (40, 666)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rabbit</td>
<td>Aorta</td>
<td>(237, 188, 530)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Ear artery</td>
<td>(596)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jugular vein</td>
<td>(39)</td>
</tr>
<tr>
<td></td>
<td>Cat</td>
<td>Cerebral artery</td>
<td>(697)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jejunum</td>
<td>(40)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Terminal ileum</td>
<td>(38)</td>
</tr>
<tr>
<td>Dog</td>
<td>Carotid artery</td>
<td>(150)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Saphenous vein</td>
<td>(270)</td>
</tr>
<tr>
<td>Cholinergic</td>
<td>Rat</td>
<td>Aorta</td>
<td>(137)</td>
</tr>
<tr>
<td>(muscarinic)</td>
<td></td>
<td>Anococcygeus muscle</td>
<td>(288)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Caecum</td>
<td>(622)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atria</td>
<td>(477)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fundus</td>
<td>(666)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jejunum</td>
<td>(654)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mesenteric artery</td>
<td>(137)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Portal vein</td>
<td>(137)</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Atria</td>
<td></td>
<td>(79)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Bladder</td>
<td>(422)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Species</th>
<th>Tissue</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dopamine</td>
<td>Rabbit</td>
<td>Mesenteric artery</td>
<td>(96)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Middle cerebral artery</td>
<td>(492)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Splenic artery</td>
<td>(313)</td>
</tr>
<tr>
<td></td>
<td>Cat</td>
<td>Middle cerebral artery</td>
<td>(192)</td>
</tr>
<tr>
<td></td>
<td>Dog</td>
<td>Cerebral artery</td>
<td>(631)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Coronary artery</td>
<td>(683, 634)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mesenteric artery</td>
<td>(269)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Renal artery</td>
<td>(269)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Small femoral artery</td>
<td>(269)</td>
</tr>
<tr>
<td>Histamine (H₁)</td>
<td>Rat</td>
<td>Fundus</td>
<td>(666)</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Gall bladder</td>
<td>(408)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Duodenum</td>
<td>(89)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ileum</td>
<td>(30)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jugular vein</td>
<td>(138)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Taenia caeci</td>
<td>(6)</td>
<td></td>
</tr>
<tr>
<td>Rabbit</td>
<td>Aorta</td>
<td>(150, 194, 200)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Portal vein</td>
<td>(194)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jugular vein</td>
<td>(138)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal artery</td>
<td>(152)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trachea</td>
<td>(300)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vena cava</td>
<td>(194)</td>
<td></td>
</tr>
<tr>
<td>Cat</td>
<td>Extraglandular blood vessels</td>
<td>(194)</td>
<td></td>
</tr>
<tr>
<td>Dog</td>
<td>Saphenous vein</td>
<td>(636)</td>
<td></td>
</tr>
<tr>
<td>Histamine (H₂)</td>
<td>Rat</td>
<td>Stomach fundus</td>
<td>(200)</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Atria</td>
<td>(14)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Gall bladder</td>
<td>(408)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Papillary muscle</td>
<td>(14, 60)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ventricleal strip</td>
<td>(638)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ventricleal strip</td>
<td>(677)</td>
<td></td>
</tr>
<tr>
<td>Rabbit</td>
<td>Atria</td>
<td>(521)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aorta</td>
<td>(200)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Trachea</td>
<td>(213, 380)</td>
<td></td>
</tr>
<tr>
<td>Cat</td>
<td>Extraglandular blood vessels</td>
<td>(194)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>(13, 15)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Stomach (secretion)</td>
<td>(441)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vas deferens</td>
<td>(441)</td>
<td></td>
</tr>
<tr>
<td>Cholinergic</td>
<td>Rat</td>
<td>Aorta</td>
<td>(137, 139)</td>
</tr>
<tr>
<td>(muscarinic)</td>
<td></td>
<td>Anococcygeus muscle</td>
<td>(288)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Carotid artery</td>
<td>(137)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Fundus</td>
<td>(488, 666)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Jugular vein</td>
<td>(138, 139)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Mesenteric artery</td>
<td>(137)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Portal vein</td>
<td>(137)</td>
</tr>
</tbody>
</table>
range of techniques to measure contractile function. Thus, very small vessels like the cat coronary artery can be perfused at a constant rate and the perfusion pressure used as a measure of vasoconstriction (489). Alternatively, spiral strips from vessels can be cut. The advantage of such a preparation is that enough muscle can be assayed to allow measurable responses to be obtained from very small vessels. Also, the effects of receptor heterogeneity along the length of the blood vessel can be eliminated. However, there are important geometrical considerations in the preparation of spiral strips (297, 309, 491, 635). For example, the helical and circular arrangement of smooth muscle cells in canine muscular arteries can cause contractile agonists to produce varying magnitudes of contraction, the variation being dependent upon the pitch of the angle of orientation of the helix from the transverse axis of the vessel (figure 1A). At the extreme, paradoxical contraction is observed with the normally relaxant drug papaverine and paradoxical relaxation from the normally contractile drug norepinephrine (β-adrenoceptors blocked) when these preparations are mounted longitudinally (figure 1B; 491). Similar effects were observed in aortae from normal and DOCA-hypertensive rats (297). A convenient alternative is the use of rings of vascular smooth muscle mounted on opposing stainless steel hooks (326). These preparations have the advantages of convenience and ease of preparation, minimal variation of differences in smooth muscle cell orientation, and minimal damage to the intimal surface of the vessel. In view of the importance of the intima to the tissue responses of blood vessels to some agonists this could be an important consideration (242). Perfused vessels, notably the rabbit ear artery, are useful in that they allow for the study of agonists exclusively applied to the intimal or advential side of the blood vessel (169).

There are numerous methods to prepare other smooth muscle preparations. In some tissues, attention must be paid to anatomical differentiation of the muscle as, for

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Species</th>
<th>Tissue</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Opioid</td>
<td>Rat</td>
<td>Vas deferens</td>
<td>(335)</td>
</tr>
<tr>
<td></td>
<td>Guinea pig</td>
<td>Ileum</td>
<td>(291, 397)</td>
</tr>
<tr>
<td></td>
<td>Mouse</td>
<td>Vas deferens</td>
<td>(335)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(331, 335)</td>
</tr>
<tr>
<td>Substance P</td>
<td>Rat</td>
<td>Everted portal vein</td>
<td>(443)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Vas deferens</td>
<td>(155, 437)</td>
</tr>
<tr>
<td></td>
<td>Guinea pig</td>
<td>Ileum</td>
<td>(155)</td>
</tr>
<tr>
<td></td>
<td>Rabbit</td>
<td>Mesenteric vein</td>
<td>(63)</td>
</tr>
<tr>
<td></td>
<td>Cat</td>
<td>Terminal ileum</td>
<td>(63, 530)</td>
</tr>
<tr>
<td></td>
<td>Dog</td>
<td>Carotid artery</td>
<td>(156)</td>
</tr>
<tr>
<td>Vascular-venous</td>
<td>Saphenous</td>
<td>ACh</td>
<td>(154, 349)</td>
</tr>
<tr>
<td></td>
<td>Femoral</td>
<td>ACh</td>
<td>(546)</td>
</tr>
<tr>
<td></td>
<td>Crural</td>
<td>α</td>
<td>(453)</td>
</tr>
<tr>
<td></td>
<td>Umbilical</td>
<td>α</td>
<td>(592)</td>
</tr>
<tr>
<td>Smooth muscle</td>
<td>Bronchiol (lung)</td>
<td>β</td>
<td>(272, 306, 714)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>α</td>
<td>(62, 78)</td>
</tr>
<tr>
<td></td>
<td>Stomach (duodenum)</td>
<td>α</td>
<td>(306)</td>
</tr>
<tr>
<td></td>
<td>Muscularis mucosa</td>
<td>ACh,α,β</td>
<td>(680)</td>
</tr>
<tr>
<td></td>
<td>Ileum</td>
<td>α</td>
<td>(154)</td>
</tr>
<tr>
<td></td>
<td>Colon</td>
<td>α</td>
<td>(306)</td>
</tr>
<tr>
<td></td>
<td>β</td>
<td>(154)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Sphincter pupillae</td>
<td>ACh</td>
<td>(364)</td>
</tr>
<tr>
<td></td>
<td>Internal anal sphincter</td>
<td>ACh,α</td>
<td>(119)</td>
</tr>
<tr>
<td></td>
<td>Oesophagus</td>
<td>α</td>
<td>(154)</td>
</tr>
<tr>
<td></td>
<td>Vas deferens</td>
<td>α</td>
<td>(302)</td>
</tr>
<tr>
<td></td>
<td>Bladder detrusor</td>
<td>α</td>
<td>(154)</td>
</tr>
<tr>
<td></td>
<td>Ureter</td>
<td>H₁, H₂</td>
<td>(61)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tissue</th>
<th>Receptor*</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vascular-arterial</td>
<td>Femoral</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Basilar</td>
<td>5-HT</td>
</tr>
<tr>
<td></td>
<td>Dopamine</td>
<td>5-HT</td>
</tr>
<tr>
<td></td>
<td>Popliteal</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Umbilical</td>
<td>ACh,5-HT,α,α, H₁</td>
</tr>
<tr>
<td></td>
<td></td>
<td>α</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H₁,5-HT</td>
</tr>
<tr>
<td></td>
<td>Digital</td>
<td>β</td>
</tr>
<tr>
<td></td>
<td>Coronary</td>
<td>α,β</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H₁, H₂</td>
</tr>
<tr>
<td></td>
<td>Pulmonary</td>
<td>ACh,α,β</td>
</tr>
<tr>
<td></td>
<td></td>
<td>H₁</td>
</tr>
<tr>
<td></td>
<td></td>
<td>α</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5-HT</td>
</tr>
<tr>
<td></td>
<td>Crural</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Mesenteric</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Cerebral</td>
<td>5-HT,ACh,α, H₁</td>
</tr>
<tr>
<td></td>
<td>Vascular-arterial</td>
<td>Saphenous</td>
</tr>
<tr>
<td></td>
<td>Femoral</td>
<td>ACh</td>
</tr>
<tr>
<td></td>
<td>Crural</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Umbilical</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Smooth muscle</td>
<td>Bronchiol (lung)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Stomach (duodenum)</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Muscularis mucosa</td>
<td>ACh,α,β</td>
</tr>
<tr>
<td></td>
<td>Ileum</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Colon</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>β</td>
<td>(154)</td>
</tr>
<tr>
<td></td>
<td>Sphincter pupillae</td>
<td>ACh</td>
</tr>
<tr>
<td></td>
<td>Internal anal sphincter</td>
<td>ACh,α</td>
</tr>
<tr>
<td></td>
<td>Oesophagus</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Vas deferens</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Bladder detrusor</td>
<td>α</td>
</tr>
<tr>
<td></td>
<td>Ureter</td>
<td>H₁, H₂</td>
</tr>
</tbody>
</table>

* α, α-adrenergic; 5-HT, 5-hydroxytryptamine; ACh, acetylcholine; H₁, H₂, histamine; β, β-adrenergic.
example, in the rabbit urinary bladder base and body (421) or the longitudinal versus circular muscle of the rat fundus (666). The guinea pig ileum longitudinal muscle strip holds advantages over the whole ileum in isolated tissue work (527). There are a wide variety of ways to mount and monitor the contraction of airway smooth muscle (295).

Cardiac muscle function can be measured either by perfusion of the heart by the Langendorff technique (95, 409, 523) or measurement of twitch contraction from isolated atria, papillary muscle, or strips of ventricle (82, 393). Cardiac sinus nodal function can be obtained from isolated right atria. The electrical stimulation of cardiac tissue requires attention to the arrangement of the electrodes if release of neurotransmitters is to be avoided (79–81). The use of a geometrically homogeneous tissue such as the papillary muscle is an advantage over preparations having irregular geometry for tension development such as strips of ventricular muscle (593, 594). Particular attention must be paid to the thickness of the cardiac muscle utilized in isolated tissue experiments since the high oxygen consumption of this tissue makes hypoxia a distinct possibility in the organ bath (82).

Certain physical procedures can alter existing isolated tissue preparations to suit special needs. For example, rabbit aorta can be effectively denervated by excision of the adventitia (68, 446). Similarly, stripping the serous coat and mesenteric attachments of vas deferentia effectively denervates this preparation (72).
E. Measurement of Tissue Responses

There are many methods of measuring the responses of various isolated tissue preparations to drugs. Responses can be measured in terms of magnitude as in isotonic shortening, isometric tonic or phasic contraction, isometric twitch contraction, or frequency (i.e., atrial rate, spontaneous motor activity). In some cases the method of recording responses does not influence the sensitivity of the preparation to agonists. Thus the sensitivity of guinea pig ileal longitudinal smooth muscle to histamine is not appreciably different when contractile responses are measured isotonically or isometrically (145). Similarly, the sensitivity of rat tail arteries to norepinephrine does not differ when isotonic and isometric responses are compared (660). In other tissues this does not appear to be true and the difference may depend upon the thickness of the preparation and the relative amount of muscle mass and receptor activation required for maximal response. Thus, in contrast to the guinea pig ileum, there is a significant difference between the concentration of carbachol required to produce half maximal isometric contraction and that needed for half maximal isometric contraction in frog rectus abdominus and leech dorsal muscle (451). In these relatively thick muscles, more agonist is required for isometric tension than isotonic shortening. This differentiation carries over to partial agonists where it was observed that, relative to the maximal response produced by potassium depolarization, the intrinsic activity of partial agonists was greater in these muscles when measured isotonically as opposed to isometrically. In keeping with the concept of a greater receptor stimulation being needed for isometric contraction, the isometric responses to muscarinic agonists were more sensitive than isotonic responses to blockade by receptor alkylating agents (451).

When measuring responses isometrically, it is important to do so at $L_{\text{opt}}$, the length of tissue which produces the maximal active response (597, 598). In tissues such as cardiac muscle (593, 594) and muscular, as opposed to elastic, arteries (693), it is especially important to work at the optimum resting tension.

F. Sources of Variation in Tissues

A great deal of pharmacological inference is derived from the relative sensitivity of tissues to agonists. Many factors including animal variation with respect to agonist uptake mechanisms, numbers of viable receptors, and differences in the efficiency of stimulus-response mechanisms can cause heterogeneity in sensitivity of tissues to agonists. To a large extent, increasing the number of experiments can accommodate these errors (246).

One method of reducing the between animal variation in experiments is to use paired tissue preparations from the same animal and make comparisons between pairs of treated and control tissues. Some tissues can be divided into equal portions such as atrial halves, rings of conduit vessels and airway smooth muscles, and segments of gastrointestinal tract. Other tissues such as uterus, vasa deferentia, seminal vesicles, and anococcygeus muscles conveniently come in matched pairs.

1. Heterogeneous Receptor Distribution. Another factor to consider in the choice of isolated tissue is the homogeneity and distribution of the drug receptors. The presence of a heterogeneous population of receptors subserving antagonistic responses with respect to each other can confound the quantification of drug effects on any one of the drug receptors. The most common setting for this situation is found in the study of adrenoceptors. For example, tissues with a predominant $\alpha$-adrenoceptor population in the presence of pharmacologically antagonistic $\beta$-adrenoceptors include mouse spleen (339), rat mesenteric artery (90), and cat nictitating membrane (588). Tissues with a dominant $\beta$-adrenoceptor population in the presence of antagonistic $\alpha$-adrenoceptors include guinea pig trachea (470, 515) and rat uterus (99). Opposing populations of histamine $H_1$ and $H_2$ receptors have been reported in rat stomach fundus and rabbit aorta (200). Synergistic $\alpha$-adrenoceptors in the presence of dominant $\beta$-adrenoceptors are found in guinea pig and rat atria (278). The most common method used to detect and eliminate this problem is by using selective antagonists of the interfering receptor population. For example, the $\alpha$-adrenoceptor responses of rat veins are strikingly potentiated when the relaxant $\beta$-adrenoceptors are blocked by propranolol (136). The potentiation of the relaxant effects of histamine ($H_2$ receptors) by the antagonism of histamine $H_1$ receptors by chlorpheniramine in rabbit trachea illustrates another example of mixed receptors in an isolated tissue (381). The problem of heterogeneous receptors becomes more important when dealing with partial agonists. For example, little response can be elicited in the canine saphenous vein by dobutamine. However, blockade of the $\alpha$-adrenoceptors with phentolamine reveals a relaxant $\beta$-adrenoceptor response and blockade of the $\beta$-adrenoceptors with propranolol reveals an $\alpha$-adrenoceptor contractile response both of which cancel each other in the absence of the blocking drug (370).

There are gradients of responsiveness in tissues to agonists which coincide with anatomical orientation. For example, it has been shown that rabbit aorta is not uniformly sensitive to $\beta$-adrenoceptor agonists (8). There is a pronounced heterogeneity in rabbit trachea and bronchus in response to a variety of spasmsogens and relaxants (213). In canine aorta, a gradient of phosphodiesterase activity has been observed (644). In the rabbit basilar artery a graded responsiveness to norepinephrine, increasing from the distal to the proximal portions and to serotonin and decreasing from the distal to the proximal segment of the tissue, has been reported (263). Some of the observed heterogeneity has been ascribed to the heterogeneous distribution of receptor types. For exam-
ple, the urinary bladder of the rabbit can be divided into
the bladder body where \( \alpha \)-adrenoceptors predominate
over \( \beta \)-adrenoceptors and the bladder base where the
opposite predominance occurs (421). In the rabbit aorta,
Fleisch and coworkers (215) found that the thoracic aorta
contained a greater predominance of \( \beta \)-adrenoceptors
than the abdominal aorta. In the dog, there are mainly
\( \alpha \)-adrenoceptors in the common coronary artery, both \( \alpha \)-
and \( \beta \)-adrenoceptors in the proximal portion, and mainly
\( \beta \)-adrenoceptors in the distal coronary artery (464). Bo-
vine trachea has been shown to possess 37 times the
number of \( \beta \)-adrenoceptors as bovine lung (126). Receptor
subtypes also appear to be heterogeneously distributed
within tissues. For example, responses of rat vasa defer-
entia to selective \( \alpha \)-adrenoceptor agonists suggest a het-
erogeneity of pre- and postsynaptic \( \alpha \)-adrenoceptors in
the prostatic and epididymal portions of this tissue (427).
In dog femoral and saphenous veins \( \alpha \)-, and \( \alpha \)-adreno-
ceptors appear to coexist while in the dog femoral and
splenic artery, \( \alpha \)-adrenoceptors predominate (177). In
canine trachea \( \alpha \)-adrenoceptors appear predominant
while in the peripheral airways \( \alpha \)-adrenoceptors domi-
nate contraction (45). In guinea pig airways, the re-
ponses to various \( \beta \)-adrenoceptor agonists and antago-
nists suggest that the proportion of \( \beta \)- to \( \beta \)-adrenoce-
ptors decreases from the trachea to the bronchus and
intrapulmonary airways (713).

The heterogeneous distribution of drug receptors in
various isolated tissues should be kept in mind when
quantitative comparisons of drug effects, especially
within tissues, are made. One previously mentioned
method of reducing the consequences of such heteroge-
nity is the use of the complete tissue for assay by, for
example, preparation of a spiral strip.

2. Animal Maturity. Age has been found to affect the
receptor density and/or distribution and the reactivity
of various isolated tissues. For example, the responsiv-
eness of rat hearts to ouabain (255), the sensitivity of rat
and guinea pig trachea to isoproterenol (2), the histamine
H2-receptor-mediated responses of rabbit aortae (321),
and the effects of 5-HT agonists in rabbit aortae (301)
have been shown to decrease with animal maturity.
The sensitivity of responses in rat vasa deferentia postulated
be to due to stimulation of presynaptic \( \alpha \)-adrenoceptors
also is inversely proportional to age (183). In contrast,
age has been shown to increase the contractions of rat
aortae to norepinephrine and serotonin (135). There is
substantial evidence that \( \beta \)-adrenoceptor-mediated re-
xaction of rabbit and rat thoracic aortae decreases with
increasing age (201, 212, 215, 288). This is in contrast to
the lack of effects of age on the \( \beta \)-adrenoceptor-mediated
responses of rat and rabbit portal vein (214). The re-
ponses of rabbit trachea to several agonists was found
to change with age (300). The predominance of one
receptor type over another can vary with animal maturity
as well. For example, the dominant positive inotropic
responses of rat atria to phenylephrine shift from being
predominantly \( \beta \)-adrenoceptor-mediated in young rats to
\( \alpha \)-adrenoceptor-mediated in adult rats (299). This is in
accordance to the measured decreased number of \( \beta-
adrenoceptors (128) and increased number of \( \alpha \)-adren-
ceptors (403) in rat hearts with age. While the effects of
age would not be expected to produce serious variation
in tissues from carefully matched animals, they could
account for differences observed in different laboratories.

G. Comparisons between Isolated Tissues

Often it is desirable to compare the responses of iso-
lated tissues from animals either between species or in
the same species in different physiological or pathological
states. For example, much research has been conducted
on the relative contractile activity of blood vessels from
normal and hypertensive rats. In these comparisons, the
scale of responsiveness should be carefully normalized to
eliminate differences due to muscle mass and thickness.
Thus, simple comparisons of actual responses in New-
tons may be misleading. It is important to compare the
different tissues not at the same resting tension but
rather at the optimal resting tension for each tissue. One
way to normalize active tension is to use a scale that
makes active muscle tension, as a function of resting or
passive tension (or length), superimposable or parallel
with the same maximum for the two types of tissue
preparations. For example, Wyse found the force per
cross sectional area of muscle a suitable scale for com-
paring muscular arteries and the force per unit of total
volume for comparing elastic arteries of differing mass
in rats (707). In comparing responses to agonists, the
effects of muscle mass on diffusion coupled with differ-
ences in uptake, degradative metabolism, and innerva-
tion also should be considered as complicating factors.

III. Equilibrium Conditions in Isolated Tissues

The equations derived to describe drug and receptor
interactions assume free diffusion and the establishment
of thermodynamic equilibria. In well-mixed biochemical
reactions these are reasonable assumptions but in many
isolated tissue preparations the assumption that these
conditions are attained enters more the realm of wishful
thinking (698). Accurate knowledge of the magnitude of
the independent variable is a prerequisite to the gener-
ating of meaningful dependent variables and in pharma-
cological experiments, the dependent variables that yield
information about drugs and drug receptors are tissue
responses and the critical independent variables are the
concentrations of drug at the receptor. It is important to
know the concentration of drug at the receptor, since it
is from this parameter that all estimates of drug con-
stants such as affinity and efficacy are made.

The need for the attainment of equilibrium conditions
in isolated tissues has been stressed (230, 231, 552, 567,
663). A concise statement of the assumptions made
(sometimes tacitly) in isolated tissue experiments was presented by Furchgott (232) and is given in table 3 as a focus for discussion. Each of these points will be considered in some detail in this review.

The activation of receptors by drugs in isolated tissues can be divided into three processes: 1) the delivery of drug from the organ bath solution to the receptor compartment, 2) the interaction of the drug with the receptor, and 3) in the case of agonists, the transduction of receptor stimulus into tissue responses (27). These latter two processes have been termed the "pharmacodynamic" phase of drug action by Ariens (23, 25, 271). The first step is the delivery of drug to the drug receptor, a bulk diffusion phenomenon that can be affected by chemical, physical, and biochemical processes.

A. Chemical Degradation of Drugs

Since the driving force of bulk diffusion is a concentration gradient, any process that changes concentration will affect the rate of diffusion. One way in which drug concentration can be changed in an organ bath is by chemical degradation. Perhaps the most well-known example of the chemical instability of drugs is the tendency of catecholamines to oxidize in the presence of trace amounts of divalent cations or in alkaline pH (293, 294). The addition of disodium EDTA (228) or ascorbate to the bathing medium prevents this chemical degradation. In the absence of these measures, the destruction of catecholamines can be quite rapid; for example, the half-time for degradation of 0.3 μM norepinephrine in physiological saline is 8 to 9 min at 37°C and 25 to 26 min at 32°C (330). The half-time at 37°C is within the time span required for the attainment of steady state responses in many isolated tissue preparations such as rabbit aorta, guinea pig trachea, and guinea pig extensor digitorum longus, thus inclusion of antioxidants to the bathing medium would be highly recommended. Another example of chemical instability in physiological saline is the rapid inactivation of prostaglandins (219). The degradative process can be optically catalyzed as for example the photolysis of aqueous solutions of lysergic acid diethylamide (681) or the well-known instability of the calcium channel antagonist, nifedipine, in the presence of light.

The adsorption of drugs to the surface of the organ bath can serve as a physicochemical process of drug removal from the receptor compartment. This methodological problem has been encountered with basic amines such as promethazine (442) where substantial dilution errors were introduced into experiments by the use of glass containers. Adsorption to glass surfaces has been encountered with peptides such as substance P. The addition of 0.1% bovine serum albumin (683), dithiothreitol (353), or the use of polypropylene organ baths (223) have been found to eliminate the problem. The adsorption of substances to surfaces and subsequent leaching into fresh physiological solution in future experiments also can be a significant methodological problem. This effect has been encountered with rubber surfaces [propranolol (234)], silicone surfaces [haloperidol (595A)], and glass surfaces [1-isoproterenol (234); guanabenz (427)].

B. Release of Endogenous Substances

Disparity between the concentration of drug in the organ bath and active drug at the receptor site can arise if the drug promotes release of an endogenous substance in the tissue. It would be expected that the magnitude of the response would be increased if the endogenous substance produced the same qualitative response or decreased if the substance produced a pharmacologically antagonistic response. The most common type of release encountered in pharmacological experiments is that of endogenous neurotransmitters such as norepinephrine and acetylcholine. Table 4 shows a number of agonists that release an endogenous substance (indirect agonist)

---

**TABLE 3**

Optimal conditions in experiments for the pharmacological characterization of drug receptors in isolated tissues*

1. The response of the tissue preparation to an agonist should be due solely to the direct action of the agonist on one type of receptor. It should not be resultant of actions on more than one type of receptor, nor should it be due even partially to indirect action (e.g., release of endogenous norepinephrine).

2. The altered sensitivity to an agonist in the presence of a competitive antagonist should be due solely to competition between the antagonist and the agonist for the receptor. The altered sensitivity after treatment with an irreversible antagonist should be due solely to inactivation of the receptor.

3. The response following the addition of a given dose of agonist should be measured at the maximal level reached. In the most suitable tissues, this maximal level is maintained for a reasonable length of time.

4. In the case of either an agonist or competitive antagonist, the free concentration in the external solution should be maintained at a steady level at the time a response is measured, and should be known. In the case of an irreversible antagonist, the concentration in the solution should be essentially zero during the measurement of responses.

5. In the case of either an agonist or competitive antagonist, the concentration in the region of the receptors should be in diffusion-equilibrium with that in the external solution at the time a response is measured. To meet this condition, the rate of removal of drug from this region due to enzymic action, transport into cells, and binding should be negligible compared with the rate due to diffusion back to the outside solution. In the case of an irreversible antagonist, the fraction of receptors which is not inactivated should remain constant over the total period during which responses are measured.

6. The experimental design should include proper controls to permit measurements of, and corrections for, any changes in sensitivity of the tissue preparation to agonists during the course of an experiment that are not due to addition of an antagonist.

---

* Reprinted with permission from Furchgott (232).
### Table 4

<table>
<thead>
<tr>
<th>Agonist</th>
<th>Species</th>
<th>Tissue</th>
<th>Indirect Agonist</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dopamine</td>
<td>Guinea pig</td>
<td>Atria</td>
<td>Norepinephrine</td>
<td>(496)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atria</td>
<td>Norepinephrine</td>
<td>(395)</td>
</tr>
<tr>
<td></td>
<td>Rat</td>
<td>Gastric fundus</td>
<td>Norepinephrine</td>
<td>(414)</td>
</tr>
<tr>
<td>Histamine</td>
<td>Cat</td>
<td>Trachea</td>
<td>Norepinephrine</td>
<td>(204, 436)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atria</td>
<td>Norepinephrine</td>
<td>(3)</td>
</tr>
<tr>
<td>4-Methylhistamine</td>
<td>Rabbit</td>
<td>Atria</td>
<td>Norepinephrine</td>
<td>(621)</td>
</tr>
<tr>
<td>2-(2-Pyridyl)ethylamine</td>
<td>Guinea pig</td>
<td>Heart</td>
<td>Norepinephrine</td>
<td>(402)</td>
</tr>
<tr>
<td>Tolazoline</td>
<td>Rat</td>
<td>Atria</td>
<td>Norepinephrine</td>
<td>(334)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Atria</td>
<td>Histamine</td>
<td>(334, 378, 423)</td>
</tr>
<tr>
<td></td>
<td>Guinea pig</td>
<td>Atria</td>
<td>Acetylcholine</td>
<td>(334)</td>
</tr>
<tr>
<td>Clonidine</td>
<td>Rabbit</td>
<td>Aorta</td>
<td>Histamine</td>
<td>(87)</td>
</tr>
<tr>
<td></td>
<td>Guinea pig</td>
<td>Atria</td>
<td>Histamine</td>
<td>(378, 423)</td>
</tr>
<tr>
<td>Cimetidine</td>
<td>Rat</td>
<td>Uterus</td>
<td>Norepinephrine</td>
<td>(648)</td>
</tr>
<tr>
<td>Impromidine</td>
<td>Rabbit</td>
<td>Atria</td>
<td>Norepinephrine</td>
<td>(332)</td>
</tr>
<tr>
<td>5-Hydroxytryptamine (5-HT)</td>
<td>Guinea pig</td>
<td>Ileum</td>
<td>Acetylcholine</td>
<td>(151, 509)</td>
</tr>
<tr>
<td>Bradykinin</td>
<td>Rabbit</td>
<td>Pupillary sphincter</td>
<td>Substance P</td>
<td>(115)</td>
</tr>
<tr>
<td>Substance P</td>
<td>Rat</td>
<td>Mast cells</td>
<td>Histamine</td>
<td>(202)</td>
</tr>
<tr>
<td>Adenosine</td>
<td>Rat</td>
<td>Tail artery</td>
<td>5-HT</td>
<td>(100)</td>
</tr>
</tbody>
</table>

To produce responses in some isolated tissues. A comprehensive review of phenylethylamines and other drugs that release norepinephrine has been given by Trendelenburg (642).

Various methods are available to eliminate the release of indirect agonists in isolated tissues. If the indirect agonist (released substance) produces responses by activation of a receptor distinct from the receptor of interest, then selective antagonists can be used to eliminate the complicating effects. However, this sometimes is not possible if the indirect agonist activates the same receptor as the direct agonist; i.e., for obvious reasons, the direct effects of ephedrine on β-adrenoceptors cannot be separated from the effects of released norepinephrine by the addition of propranolol. The alternative here is to deplete the tissue stores of endogenous norepinephrine by 6-hydroxydopamine treatment in vivo (624, 642), or in vitro (17), by physical removal of the neural plexus (68, 446) or, most commonly, by pretreatment of the animal with a catecholamine-depleting drug such as reserpine (447, 642).

The effects of a competitive antagonist on concentration-response curves to an agonist may provide a clue as to whether the responses to the agonist are due to direct activation of a receptor or to release of an indirect endogenous agonist. Black and coworkers (76) have presented a theoretical model which predicts that under a variety of circumstances the concentration-response curve to an agonist that produces an effect by release of an indirect agonist will be shifted to the right by a competitive antagonist but also show a depressed maximal response. Experimentally, this was demonstrated by the shift and depression of concentration-response curves to tyramine by propranolol and sotalol in rat atria (76). As shown in figure 2, the maximal responses to tyramine are progressively depressed with increasing dextral displacement of the concentration-response curves by propranolol. Similar effects have been reported for tyramine inhibition by propranolol (625) and phen tolamine (207). The model predicts that the receptor

![Fig. 2. Effects of propranolol on responses of rat left atria to tyramine. A. Dynograph tracing of electrically stimulated contractions of rat left atria; responses to tyramine before and after propranolol (50 nM). B. Concentration-response curves to tyramine. Ordinates: Responses to tyramine as fractions of the maximal control response. Abscissae: Logarithms of molar concentrations of tyramine. Responses in absence (○, n = 17) and presence of propranolol 10 nM (□, n = 5), 50 nM (△, n = 7), and 200 nM (□, n = 5). Bars represent S.E.M. Reprinted with permission from Black et al. (76).](image-url)
occupancy ($\rho$) achieved by an agonist $[A]$, which produces release of an indirect agonist $[I]$, is given by (76):

$$\rho = \frac{1}{1 + \frac{K_I}{\theta} \left( 1 + \frac{K_A}{[A]} \right)}$$

(2)

where $K_A$ and $K_I$ refer to the equilibrium dissociation constant of agonist $A$ for the site of release and $I$ for the receptor, respectively, and $\theta$ a measure of the releasable pool of indirect agonist (e.g., the maximal concentration of $I$ achieved by saturating concentrations of $A$) with dimensions of concentration. It can be seen from Eq. 2 that even in the absence of a competitive antagonist, the maximal receptor occupancy by the indirect agonist may not be achieved by any amount of agonist $A$ if $K_I/\theta$ is large; i.e., if the pool is small (low $\theta$) or $K_I$ large (low affinity of $I$ for the receptor). Depending upon the effective receptor reserve in the tissue, which is a function of the efficacy of $I$ and the efficiency of the stimulus response mechanisms in the tissue, a high ratio of $K_I/\theta$ may preclude production of a maximal response by $A$. In the presence of a competitive antagonist $B$, the receptor occupancy becomes:

$$\rho' = \frac{1}{1 + \frac{K_I}{\theta} \left( 1 + \frac{K_A}{[A]} \right) \left( 1 + \frac{[B]}{K_B} \right)}$$

(3)

where $K_B$ is the equilibrium dissociation constant of the antagonist for the receptor. It can be seen intuitively from Eq. 3 that the tendency of values of $K_I/\theta$ to depress the maximal response to $A$ is exacerbated by the addition of competitive antagonist; i.e., a competitive antagonist will tend to depress the maximal responses to agonist $A$. The amount of depression of the maximal response by $B$ will depend upon the size of the releasable pool $\theta$, the affinity and efficacy of the indirect agonist $I$, and the efficiency of the stimulus response mechanisms in the tissue. Therefore, in a tissue with a high receptor reserve and a large pool of releasable endogenous agonist, a competitive antagonist may produce parallel shifts of the control concentration-response curve (with no depression of maximum) to a releasing agent. This situation would closely resemble what would be expected of a direct agonist. However, if the concentration-response curves to an agonist are shifted to the right and depressed by a competitive antagonist in a pattern like that shown in figure 2, this would suggest that the agonist was releasing an endogenous agonist in the tissue.

Finally, the effects of drugs not mediated by drug receptors can obscure isolated tissue experiments. For example, the effects of high concentrations of histamine on organ bath pH have been noted in rabbit atria (178, 332), guinea pig pulmonary artery (296), and rabbit trachea (381). In this latter preparation, relaxant responses to histamine could be elicited which were insensitive to histamine $H_2$-receptor-blocking drugs but were eliminated by neutralization of the acidic stock solution of histamine.

C. The Removal of Drugs by Tissues

1. Diffusion into Isolated Tissues. A drug added to the solution bathing a tissue in an organ bath must diffuse into the receptor compartment to produce an effect. There are mathematical models to describe this process which are relevant to this discussion because they highlight some factors that can seriously affect parameters thought to reflect drug-receptor interactions in tissues. For the purposes of these discussions, the bathing solution is assumed to be an infinite reservoir of drug at constant concentration.

The dissolution of drug from the point of injection into a well-mixed organ bath occurs relatively rapidly. For example, Cuthbert and Dunant (164) found that conductance changes across electrodes in a 50-ml bath produced by injection of potassium chloride solution occurred within 0.05 sec of injection. However, there are reasons to suppose that the process of free diffusion which controls the access of drug to the surface of the tissue does not describe the entry of drug into the tissue.

It is known that the diffusion coefficient of drugs in tissues is slower than in free solution (101, 315, 401). For example, the diffusion of acetylcholine into rat diaphragm is 0.14 times that in free solution (400) while the diffusion of norepinephrine in the medial layer of rabbit aorta is 0.1 times the rate in free solution (67). One method of accommodating these phenomena is by defining a tortuosity factor (494, 495, 672) designated $\lambda$. Thus the diffusion coefficient of a drug in a tissue $D'$ relates to the diffusion coefficient of the drug in free solution $D$ by the following equation:

$$D' = \frac{D}{\lambda^2}. \quad (4)$$

The rationale for such a factor is that while the diffusion coefficient measures the random rate of travel by a straight line, the path that a drug must take through a tissue is considerably longer since it must accommodate the numerous obstructions in the morphological organization of the muscle.

With diffusion equations derived by Crank (158), it is possible to calculate the theoretical rate of diffusion of a drug into tissues. Thus, for a tissue which can be approximated geometrically by a cylinder, the rate of change of drug concentration $C/\delta t$ across the radius of the muscle $r$ is given by:

$$\frac{\partial C}{\partial t} = \frac{1}{r} \frac{\partial}{\partial r} \left( D \frac{\partial C}{\partial r} \right). \quad (5)$$

A graphic solution for Eq. 5 was provided by Venter (672) for a cat papillary muscle 1 mm in diameter with a tortuosity factor, estimated to be 1.44 for this tissue (495), and is shown in figure 3. It is interesting to note...
that complete diffusion of isoproterenol to the center core of the tissue requires 10 min.

The rate of equilibration of the extracellular space with \(^{3}H\)inulin is known to vary with tissue type. Watson (682) has shown this time to be 30 sec in guinea pig ileal longitudinal muscle and 300 sec in rat vas deferens. Michelson and Shekovenkov (451) have shown a range from 10 sec in guinea pig ileum to 400 sec in the protractor pharynx of holothura. One factor thought to be responsible for these differences in diffusion rates for different tissues is tissue thickness. The diffusion time is related to tissue thickness \((L)\) by the following equation (573):

\[
t = \frac{L^2}{2D}. \tag{6}
\]

Considering the morphological architecture of tissues to be reflected by the tortuosity factor, this equation can be modified to:

\[
t = \frac{L^2 \lambda^2}{2D} \tag{7}
\]

where \(D\) is the diffusion coefficient of the drug in free solution. Factors which affect \(L\) will correspondingly alter diffusion time.

Another determinant of diffusion time is the conformation of the extracellular space. The extracellular space is a complex structure (274) and should be considered a dynamic compartment rather than a stiff box (650). The size of the extracellular space is affected by stretching and relaxation (693) and this can affect diffusion. For example, the hydrolysis of acetylcholine by acetylcholinesterase is greater in stretched rather than contracted guinea pig ileum (462). The orientation of the tissue may be a factor as well in that diffusion paths for drugs may be longer in some physical configurations of tissues. For example, the \(T_{1/2}\) for diffusion into thin but twisted longitudinal muscle strips of guinea pig ileum is longer than that for whole guinea pig ileum (164). Finally, changes in the effective extracellular space must be considered for drugs that have no visible effect on muscle tone but do nevertheless affect \(T_{1/2}\) for diffusion (650).

The effects of diffusion on drug entry into tissues are not in themselves capable of seriously affecting the measurement of drug receptor parameters. However, these factors, when coupled to an active uptake process for drugs within the isolated tissue, take on a new dimension of relevance to in vitro experiments.

2. Drug Removal Processes in Isolated Tissues. When a tissue possesses an active removal mechanism for a drug then the response to that drug is governed by the steady-state concentration of the drug in the receptor compartment which in turn is controlled by the relative rate of drug entry (by diffusion) and removal (by tissue uptake). Depending upon these relative rates there could be a constant deficit of drug at the receptor when compared to the concentration in the organ bath. Thus, if the rate constant for tissue uptake of a drug exceeds the rate constant for diffusion into the tissue by a factor of 10, then a 10 \(\mu\)M drug concentration in the organ bath translates to a steady-state concentration at the receptor of 1 \(\mu\)M; i.e., tissue uptake shifts concentration-response curves of agonists to the right. Inhibition of tissue uptake corrects this deficit and allows more of the drug added to the organ bath to reach the receptor thus the concentration-response curves to agonists taken up by tissues shift to the left after inhibition of the tissue uptake processes, i.e., tissue sensitization to the agonist. This type of sensitization, termed deviation supersensitivity by Fleming (216), should be distinguished from changes in tissue sensitivity brought about by changes in stimulus response mechanisms. The maximal deviational sensitization obtained in any one tissue reflects the effective importance of uptake in that tissue (the magnitude of drug deficit at the receptor) and is controlled by those factors which control the rate of drug entry (\(D, \lambda, L\)) and removal (the \(K_m\) and \(V_{max}\) of an uptake process described by Michaelis-Menten kinetics).

Differences in the factors reflecting tissue size and morphology \((\lambda, L)\) can cause differences in the effects of uptake within a given tissue type. Ebner and Waud (191) have derived a useful model to describe certain effects of tissue geometry on the observed sensitization of tissues to agonists. Thus, variable tissue thickness \((L)\) was expressed as an increased volume to surface area ratio \((V/S)\). Eq. 8 describes the concentration of agonist in the

---

**Fig. 3.** Calculated distribution of isoproterenol and polymeric isoproterenol (12,800 mol. wt.) in a 1-mm diameter cat papillary muscle at 25°. Ordinates: Fraction of organ bath concentration within the muscle. Abscissae: Distance from muscle surface. Numbers refer to time in seconds for free isoproterenol and, in parentheses, polymeric isoproterenol (12,800 mol. wt.) in a 1-mm diameter cat papillary muscle. Reprinted with permission from Venter (672).
receptor compartment \([A_i]\) as it relates to the concentration in the organ bath \([A_0]\) for a tissue of volume \(V\), surface area \(S\), with an uptake process having a Michaelis-Menten constant designated \(K_m\) and maximal velocity of uptake \(J_m\) (191).

\[
[A_i] = -\frac{1}{2}[-[A_0] + K_m + (J_m/k_m)(V/S)]
+ \sqrt{\frac{3}{2}[-[A_0] + K_m + (J_m/k_m)(V/S)]^2 - K_m[A_0]}
\]  
(8)

where \(k_m\) refers to a permeant constant encompassing diffusion and tortuosity. Note how the concentration of agonist in the receptor compartment \([A_i]\) relates to the concentration in the organ bath \([A_0]\), the avidity of uptake \((J_m/K_m)\) and the diffusional \((k_m)\) and geometrical \((V/S)\) characteristics of the tissue. Ebner (189) used Eq. 8 to calculate the theoretical deficit of agonist at the receptor produced by an uptake process with given values of \((J_m/k_m)\), \((V/S)\), and \(K_m\). Figure 4 shows the relationship between the concentration of an agonist in the organ bath and the concentration at the receptor (extracellular space). This figure illustrates the three general regions of deficit of agonist in the receptor compartment: 1) at concentrations of \([A_0]\) below the effective \(K_m\) for agonist uptake, there is a constant ratio between the steady-state concentration at the receptor and that in the organ bath; 2) as the concentration of agonist in the organ bath approaches, equals, and surpasses the effective \(K_m\) of uptake in the tissue, the concentration in the receptor approaches the concentration in the organ bath (nonlinear portions of the curves in figure 4); and 3) when the concentration of drug in the organ bath is well above the effective \(K_m\) of uptake in the tissue, then uptake is saturated and the concentration of agonist at the receptor equals the concentration in the organ bath. Ebner and Waud (191) used Eq. 8 to predict the effects of various ratios of \(V/S\) on concentration-response curves. Figure 5A shows that as \(V/S\) increases, concentration-response curves shift to the right and become steeper than the concentration-response curve to the agonist which would be obtained in the absence of uptake. In an elegant series of experiments, they then went on to correlate the sensitivity of guinea pig papillary muscles to norepinephrine with the thickness of the muscle (figure 5B), a positive correlation which graphically illustrated the tangible effect of \(V/S\) on uptake and the estimation of agonist potency.

When dealing with complex whole tissues, certain other geometrical factors become important such as whether the uptake process functions as an effective diffusion barrier (356) and the relative geometry of uptake and receptors (643). Ingenious experiments with techniques such as surface-selective perfusion of blood vessels (169) and inhibition of diffusion into strips (499) or rings (448) by application of selective diffusion barriers have demonstrated nonhomogeneously distributed removal mechanisms in vascular smooth muscle. For example, the greater sensitivity of perfused rabbit ear artery to norepinephrine when applied to the intimal rather than the adventitial surface (170, 172, 355) has been attributed to the nonhomogeneous distribution of adrenergic innervation in this tissue (170, 172). A nonhomogeneous distribution of neuronal and extraneuronal uptake mechanisms has been proposed for rabbit aorta (65, 66, 420, 500). Heterogeneity in the relative location of uptake processes within a tissue can be compounded by uneven sensitivity of muscle cells to agonists within the tissue. This latter factor has been proposed for rabbit aorta (501) and sheep carotid artery (279).

The aspects of heterogeneous distribution of uptake processes that are relevant to drug receptor responses relate to the relative geometry of the sites of uptake and the receptors. For example, considering the neuronal uptake of catecholamines as the site of loss, Trendelenburg (643) shows the poor correlation between the density of adrenergic innervation of tissues and the sensitivity to norepinephrine and highlights the correlation of sensitivity to neuromuscular interval (the distance from the nerve terminal to the muscle) given by Verity (676). It should be noted that neuromuscular distance may be superseded in importance in some tissues by asymmetry of innervation [i.e., rabbit ear artery (170, 174)]. Relative
3. Consequences of Uptake Inhibition in Isolated Tissues. The previous discussion has considered how an uptake mechanism for an agonist in a tissue coupled with various diffusion parameters can combine to produce a deficit of agonist at the receptor with respect to the concentration in the organ bath. Under these conditions, the potency of that agonist will be underestimated. To measure the true potency of an agonist for which the tissue possesses an uptake mechanism the uptake mechanism must be adequately inhibited or made otherwise inoperative. Inhibition of agonist uptake produces sinistral displacement of the concentration-response curve to the agonist if the conditions regarding the relative rate constants for uptake and diffusion are favorable and the concentrations of agonist in the organ bath do not saturate the uptake process (i.e., \([A] \ll K_m\)). In a poorly coupled tissue where very high agonist concentrations are required to produce responses, intuitively it might be supposed that a saturable uptake process may not be an important determinant of tissue sensitivity since presumably the high agonist concentrations would saturate uptake. However, the concentrations required to saturate uptake in a structured isolated tissue may differ from those predicted from biochemical experiments. There are two possible reasons for this. Firstly, the true \(K_m\) for the uptake process in a tissue may be greater because of the stationary water layer surrounding all isolated tissues in an organ bath. This layer functions as a diffusion barrier and can cause low permeability coefficients for transport processes and a higher than normal \(K_m\) (702). The thickness of this unstirred layer, estimated in tissues to be from 70 to 220 µm, can be made larger by an increase in the viscosity of the bathing medium (164) and decreased by stirring (165). For example, the thickness of the unstirred layer for rat jejunum decreased from 198 µm to 141 µm and in rat ileum from 217 µm to 159 µm with stirring (702). The half-time for diffusion \(T_{1/2}\) is related to the thickness of the unstirred layer \(d\) by the following equation (702):

\[
t_{1/2} = \frac{0.38d^2}{D}\]

(9)

where \(D\) is the coefficient of diffusion of the drug in free solution. Eq. 9 shows the effects that large unstirred layers, and therefore lack of stirring in the organ bath, can have on diffusion of drugs into the tissue.

The unstirred layer can grossly affect \(K_m\) of an uptake process in a tissue. The differences between the \(K_m\) observed in an isolated tissue and that obtained in a well-mixed biochemical experiment (difference = \(\Delta K_m\)) is given by (589):

\[
\Delta K_m = \frac{d \cdot V_{\text{max}}}{D}.
\]

(10)
It can be seen from Eq. (10) that the greater the maximal velocity of the uptake process and the larger the thickness of the unstirred layer (d), the more disparate is the $K_m$ in isolated tissues from the biochemical estimate. Henseling (308) has pointed out that in rabbit aorta, diffusional barriers falsify the kinetic constants for the uptake of $[^3H]$norepinephrine and noted a steep concentration gradient of norepinephrine within this tissue if entry was restricted to one surface only.

A disparity between the effective $K_m$ of the uptake process in the tissue and a biochemical estimate can occur also because of the concentration gradient of substrate created by the combination of ordered matrix of uptake sites in a tissue and slow diffusion. Thus, while a concentration of drug greater than the $K_m$ may be present in the organ bath, the fact that the drug must pass through a matrix of uptake sites which depletes the concentration as it diffuses into the tissue may produce a large deficit between the concentration in the organ bath and that in the tissue (317). The importance of this effect is, as expected, dependent upon the relative rates of diffusion and uptake (281):

$$\frac{[A_i]}{[A_0]} = 1 - \left( \frac{V_{\text{max}}}{n \cdot D' \cdot [A_0]} (I^2 - r^2) \right) \quad (11)$$

where $[A_i]$ is the concentration of substrate at point $r$ in a tissue of radius 1, $[A_0]$ is the concentration of substrate in the bathing medium, $V_{\text{max}}$ the maximal velocity of uptake and $D'$ the diffusion coefficient of the drug in the muscle (i.e., $\lambda^2 \cdot D$). For this equation it is assumed that $[A_0] \gg K_m$ and $n = 2, 4, 6$ depending upon whether the tissue can be approximated by a slice, cylinder, or a sphere, respectively. Thus, in the case of a very high $[A_0]$, $[A_i]/[A_0]$ will approach unity but under conditions where $[A_0]$ is already greater than $K_m$, and especially when $V_{\text{max}}$ is high and diffusion is slow, a concentration gradient of substrate can still be formed in the tissue. There are examples of this effect in isolated tissues where it was found that the apparent $K_m$ for the degradation of acetylcholine by acetylcholinesterase in rat diaphragm (460, 461) and guinea pig ileum (462) was 10 times greater than that in tissue homogenates. These disparities arise because the concentrations of acetylcholine in the extracellular space are considerably lower than those in the organ bath. Green (281) gives numerous other examples of this phenomenon.

The quantitative relationship between the degree of uptake inhibition by a competitive inhibitor of uptake I (with an equilibrium dissociation constant for the site of uptake of $K_I$) can be predicted from an equation based on models by Waud (685) and Furchgott (232). Thus, assuming $[A_i] \ll K_m$, the sensitization of a tissue to an agonist can be predicted by (367, 371):

$$x = \frac{[A]}{[A']} = \frac{y \left( 1 + \frac{[I]}{K_I} \right)}{y + \frac{[I]}{K_I}} \quad (12)$$

where $[A]$ and $[A']$ refer to equiactive molar concentrations of agonist before and after uptake inhibition, respectively, and the ratio $[A]/[A']$, designated $x$, refers to the sensitization of the tissue to the agonist produced by uptake inhibitor $[I]$. The maximal sensitization obtainable in any tissue (after complete inhibition of uptake, $[I] \gg K_I$), designated $y$, is given by (232):

$$y = \frac{V_{\text{max}}}{k_i \cdot K_m} \cdot \frac{1}{\left( 1 + \frac{[A]}{K_m} \right)} + 1 \quad (13)$$

In this equation, $V_{\text{max}}$ and $K_m$ refer to the maximal rate of uptake and the equilibrium dissociation constant of $[A]$ for the uptake sites. The term $k_i$ is a transfer rate constant [the reciprocal of the resistance term used by Waud (685)]. Before considering the quantitative relationship between tissue sensitization ($x$) and uptake inhibition some interesting aspects of the maximal sensitization ($y$) should be noted. From Eq. 13 it can be seen that if $[A] \gg K_m$, i.e. if the concentration of agonist saturates uptake, then $y$ will tend toward unity. In this case, the saturation of the uptake process allows no effective removal and therefore no deficit of $[A]$ at the receptor and no sensitization will be observed upon uptake inhibition. Large maximal sensitizations will occur if the tissue has a high maximal rate of uptake (large $V_{\text{max}}$) or poor diffusion characteristics (low $k_i$). The diffusion characteristics depend upon geometrical and morphological factors and since these can vary within the same tissue type (i.e., with age of animal, variations in the removal of access barriers such as fatty tissue or adventitia), variance in $y$, the maximal sensitization obtainable, could be expected to occur. For example, the maximal sensitization of guinea pig trachea to isoproterenol after inhibition of extraneuronal uptake can be quite variable [5.0 (483); 8.5 (367); 30 (222)]. Figure 6A shows theoretical concentration-response curves for two tissues both with identical uptake processes (equal $K_m$ and $V_{\text{max}}$). However, the diffusion characteristics differ in that $k_i$ for tissue II is 0.1 $\times$ $k_i$ for tissue I. The slower diffusion into tissue II produces a 10 times greater deficit of agonist at the receptor; i.e., the potency of $A$ in tissue I is 10 times greater than in tissue II (curve A). This calculation illustrates that diffusional differences alone can produce varying effects of an uptake process with a given $K_m$ and $V_{\text{max}}$ in a variety of tissues. This is shown by the differences between the true concentration-response curves to the agonist and the observed potency as distorted by the uptake process.

The relative rates of uptake and diffusion also have relevance to the concentrations of uptake inhibitor required to completely inhibit the uptake process in a tissue. From Eq. 12 it can be seen that the larger is $y$, the greater must $[I]/K_i$ be to produce maximal sensiti-
zation. Figure 6A shows that a given concentration of uptake inhibitor \([I]/K_1 = 30\) produces very near maximal sensitization for tissue I but less than maximal sensitization in tissue II (compare curves B and C for each tissue). The dependence of tissue sensitization, as a fraction of the maximal sensitization possible, upon the concentration of uptake inhibitor is shown in figure 6B for a series of tissues with different maximal possible sensitizations (variable \(y\)). Note that for tissues that demonstrate a low maximal sensitization to agonists (\(y = 2\)), the concentration of uptake inhibitor required for near maximal sensitization (i.e., 90%) is 10 times the \(K_1\) for uptake inhibition. This concentration of uptake inhibitor would produce only 20% maximal sensitization in a tissue with a large maximal sensitization (i.e., \(y = 50\)) (367). In these terms it would be incorrect to extrapolate maximally effective concentrations of uptake inhibitors from one tissue to another. Experimental evidence for this effect was obtained by comparing the sensitization of various tissues from guinea pigs to norepinephrine produced by cocaine (see figure 6C).

A logarithmic metameter of Eq. 1 can be used to estimate the effective \(K_1\) for an uptake inhibitor in an isolated tissue (371),

\[
\log \left[ \frac{y(x - 1)}{y - x} \right] = \log[I] - \log K_1 \tag{14}
\]

where \(x\) is the sensitization of the tissue to the agonist produced by concentration \((I)\) of the uptake inhibitor and \(y\) the maximal sensitization after complete inhibition of uptake (see insert figure 6C). This method was used to measure the \(K_1\) for inhibitors of neuronal and extraneuronal uptake of catecholamines (371) and the inhibition of adenosine uptake by benzodiazepines (372) in a variety of isolated tissues and yielded values comparable to those measured biochemically. On the surface, these results suggested that Eq. 14 could be used as a quantitative method to estimate uptake inhibitor potency in isolated tissues. However, it is difficult to assess the significance of these findings since there are theoretical reasons for the estimates obtained by this method and biochemical methods to be different. These theoretic-
tical aspects relate to the differences in the diffusional pathways of substrate (agonist) in pharmacological and biochemical experiments. Biochemical estimates of the potency of inhibitors of active removal processes can vary, the magnitude of the variation being dependent upon the importance of the formation of substrate concentration gradients within the tissue. If diffusion and substrate uptake and/or degradation limits the entry of substrate into the tissue, then inhibition of the removal process may increase the degree of penetration of substrate which in turn would distort the estimate of the extent of inhibition of the removal process (281). For example, in a tissue homogenate, where substrate concentration gradients would not be expected to occur, 80% to 90% inhibition of acetylcholinesterase by DFP is required before acetylcholine effects are potentiated (48).

However, in a structured tissue, concentrations of DFP which inhibit acetylcholinesterase by 20% are sufficient to potentiate responses to acetylcholine (195, 503). This disparity may be due to the fact that inhibition of an outer core of acetylcholinesterase may enable acetylcholine to penetrate into and stimulate more muscle (281). Thus, the biochemical $K_1$ and concentrations of uptake inhibitor required to potentiate responses may not be the same.

The selectivity of the uptake inhibitor is of paramount importance in isolated tissue experiments. Theoretical calculations show that an extraordinary degree of selectivity is required for an uptake inhibitor to fully potentiate the effects of an agonist in a tissue (367). For example, if the uptake inhibitor were a very weak receptor blocking agent (i.e., at concentrations 100 times those needed for uptake inhibition), complete sensitization would not be observed at any concentration. The receptor blocking properties would become manifest at the high concentrations of uptake inhibitor ($[I]/K_I > 300$) required to fully inhibit uptake processes in some tissues and produce shifts of the concentration-response curves to the right thereby cancelling deviational sensitization. Examples of uptake blockers which also antagonize receptors can be found in metanephrine [$pK_i$ for extraneuronal uptake = 5.4, $pK_B$ for $\beta$-adrenoceptors = 4.2 (367)] and amitriptyline [$pK_i$ for neuronal uptake = 7.2, $pK_B$ for $\alpha$-adrenoceptors = 7.0 (380)]. In guinea pig trachea, metanephrine produces only 3% of the maximal possible sensitization to isoproterenol, a value consistent with the relatively low selectivity ratio (16 times) of potency for uptake over receptors (367). In rat anococcygeus muscle, virtually no sensitization to norepinephrine can be observed with amitriptyline probably because of the comparable potency of this drug for uptake inhibition and the $pK_B$ for $\alpha$-adrenoceptors (380, 415).

Most commonly, uptake inhibition produces sensitization of tissues to agonist substrates with no increase in maximal responses. This is to be expected if contraction coupling in the tissue is efficient and not all of the muscle mass needs to be activated by the agonist to produce the maximal response. There is experimental evidence in many isolated tissues that this is the case. For example, in the cat papillary muscle it has been shown that activation of the superficial muscle layers is sufficient to activate the complete muscle (51, 327, 672) and myogenic propagation has been proposed in blood vessels as well (69).

To date, there are two examples where inhibition of uptake processes in isolated tissues produce increases in the maximal responses of isolated tissues to agonists. One is in the dog saphenous vein where inhibition of catechol-O-methyl transferase increases the maximal relaxation obtained with isoproterenol, an effect more evident in thick rather than thin tissues (284). Another is the rat vas deferens where inhibition of neuronal uptake by either cocaine or desmethylimipramine increases the maximal responses to norepinephrine but not those to methoxamine (368). The mechanisms responsible for such increased maximal responses are not clear but a reasonable hypothesis could involve desensitization as a causative factor. In tissues with poor diffusion characteristics, severe concentration gradients for agonists could develop (as discussed previously) thereby causing the outer shell of muscle cells to be exposed to a much higher concentration of agonist than the inner core. This, in turn, could induce rapid receptor or muscle desensitization at the surface of the muscle. If cell-to-cell coupling within the muscle is poor and a large body of cells needs to be activated by agonist to produce the maximal response then the concentration gradient and desensitization process could combine to produce a condition whereby the mass of tissue needed to be activated for maximal response may never be achieved. Thus, the true tissue maximal response may not be realized until after the removal of the agonist concentration gradient by uptake inhibition. The rat vas deferens may be a tissue prone to such effects since cell-to-cell coupling is poor (277) and desensitization rapid (472, 695). A concentration gradient for catecholamines is further suggested by the 40 times greater estimate of the $K_1$ for cocaine inhibition of neuronal uptake, when compared to other tissues, in rat vas deferens (187). A concentration differential for norepinephrine within this tissue is supported by two findings by Pennefather who observed that the maximal response to exogenously added but not neuronally released norepinephrine was increased by cocaine (513) and that, after desensitization of this tissue by incubation with high concentrations of exogenous added norepinephrine, the maximal responses to nerve stimulation were larger than the maximal responses to exogenous norepinephrine (512). Both results would be predicted if the muscle mass activated by exogenous norepinephrine and neurally released norepinephrine were different.
IV. Quantification of Responses to Agonists

A. Dose-Response Curves

All parameters of drug receptor interaction are derived from models which in one way or another rely upon dose-response curves. A dose-response curve can essentially be described by three parameters: a maximum ordinate, a location parameter, and slope. There are many factors not related to drug receptor interaction which can affect these parameters (410, 514), thus reliable information about drug receptor constants cannot be obtained directly from the dose-response curve. Instead, null methods have been devised which neutralize the unknown influences of stimulus-response mechanisms on tissue responses. Various non-receptor-related phenomena can still confound these methods by affecting the dose-response parameter from which most, if not all, drug receptor information is derived, namely the location parameter of the dose-response curve. This parameter defines the concentration at which a defined dependent variable, a certain level of response, is obtained. The most commonly used location parameter is the EC50 (effective concentration for 50% of maximal response) which serves as the measure of potency of an agonist.

Obviously, the success of a pharmacological procedure is contingent upon accurate location parameters for dose-response curves. One of the most common sources of potential error is a disparity between the agonist concentration added to the organ bath and that which is present at the receptor; this problem has been dealt with in previous sections of this paper. Other possible problems involve random or systematic alterations in stimulus-response characteristics or receptors to produce errors in location parameters. Systematic decreases in tissue sensitivity can occur with time and frequency of exposure to an agonist, a phenomenon often given the term “desensitization.” This can be because of receptor events such as an agonist-induced conformational change of the receptor into a less sensitive form (179, 358) or a non-selective event [i.e., “fatigue,” (684)]. For example, the ionic content of smooth muscle changes after exposure to acetylcholine (508), a factor which could contribute to altered muscle sensitivity. The change need not be a decrease in responsiveness. In some tissues, response can be increased, such as the three-fold increased maximal response to α-adrenoceptor stimulation observed over a 7.5-h equilibration period in the guinea pig oesophageal muscularis mucosa (646). Spontaneous muscle tone adds another dimension of complexity to isolated tissue experiments. For example, the sensitivity of guinea pig trachea to relaxants is greatly affected by the degree of contractile tone of this muscle (105, 106). If during the course of the experiment this were to change, a systematic error in the location parameters of the concentration-response curves to relaxants in this tissue would be introduced.

Dose-response curves can be obtained by addition of single concentrations of agonist to the organ bath (either in a random or ascending order) or by cumulative addition of concentrations (661). Different tissues are more suited to one or the other method. For example, the rat vas deferens is notorious for rapid desensitization to agonists (472, 695), thus a single-dose addition procedure with adequate quiescent periods between doses gives much more satisfactory results than does cumulative addition. Guinea pig parenchymal strip also demonstrates different sensitivity to agonists depending upon whether random single-dose or cumulative-dose procedures are used (93). Tissues with slowly developing responses such as guinea pig trachea or rabbit aorta are more suited to cumulative concentration-response curves.

Uncontrolled changes in tissue sensitivity can be devastating to pharmacological experiments designed for drug receptor analysis. Control experiments considering these factors should be carried out to determine procedures to minimize such changes. Furchgott (238) suggests a “bracketing” procedure of a concentration-response curve of a standard before and after the test agonist. Another possibility would be the use of matched preparations for comparisons of single concentration-response curves or correction for changed sensitivity in untreated tissues. These latter procedures involve tacit assumptions which subordinate them to the use of a stable tissue that can function as its own control.

Agonist potency is most often measured by the EC50 (−log EC50 = pD2). The statistical parametric procedures designed for determination of differences in potency are based upon normal distributions, thus it is important that, when dealing with log normal data from semi-logarithmic concentration-response curves, geometric means be used. These, unlike converted EC50 data, are normally distributed and give proper estimates of the means and errors (218, 245, 246).

There are numerous ways to analyze data from dose-response curves (687, 688, 690). A method used to minimize subjective errors is to fit the data to a general logistic function (175, 687, 689). The threshold concentrations at the lower end of the dose-response curve are often especially subject to error. Where accurate comparisons in this region of the dose-response curve are required, a linearizational method such as the logit function (59, 197) may be useful (675). On the other end of the dose-response curve, the maximum response at infinite dose can be estimated by a double reciprocal meta- meter (153, 508). This transformation relies on the goodness of fit of the data to a hyperbola and assumes this function describes the dose-response relationship to the maximum.

Once quantitative data is obtained from the dose-response curve which reliably reflects agonist receptor interaction, then a variety of statistical methods and procedures may be applied to the data (111, 114, 182,
From this point onwards in this paper, unless stated otherwise, it will be assumed that 1) the responses of the isolated tissue emanate only from agonist added directly to the organ bath, 2) the concentration of drug at the receptor is equal to the concentration of drug added to the organ bath, 3) the responses of the tissue are a direct result of drug receptor interaction, and 4) these responses are not modified unpredictably by the stimulus response mechanism of the tissue or any other factor. Under these circumstances (exclusively) can reliable information about drug receptor interaction be obtained. As a preface to the discussion of the methods available to do this, a brief review of the rudiments of drug receptor theory is useful.

**B. Drug Receptor Theory**

The ideas and models, which on a molecular level serve to characterize the interactions of drugs with drug receptors, will collectively be referred to as drug receptor theory. There are numerous comprehensive reviews of this topic to which the reader is referred for more detailed information than will be given here (21, 228, 229, 232, 551, 654, 655, 684). Various models have been put forward to explain the complexities of drug receptor interaction, the most common one being occupation theory where it is assumed that the occupation of a receptor by a drug leads to stimulus and subsequent response. An alternative to this hypothesis is rate theory (506) which assumes efficacy to be a product of the rate of drug receptor interaction. These approaches are given continuity in the receptor inactivation theory proposed by Gosselin (275, 276). Other approaches include the conformational perturbation theory (54), the dynamic receptor hypothesis (83), the flux carrier hypothesis (428), the ion exchange model (620), and the mobile receptor hypothesis (56, 160, 347). Allosteric two-state models of receptor also have been proposed (125, 357, 627). A particularly useful comparison of the variants of allosteric models to each other and to occupation theory has been given by Colquhoun (143). Convenient comparisons of all of these models have been given by MacKay (431), Gosselin (276), and Ruffolo (551). The following analyses and procedures are derived from occupation theory but it should be noted that the resulting parameters calculated often correspond to similar constants in other receptor theories.

The Law of Mass Action is used to describe the binding of drugs to receptors (132, 133, 314, 411):

\[
\frac{[A \cdot R]}{[R_i]} = \frac{[A]}{[A] + K_A}
\]

where \([R_i]\) refers to the total concentration of receptors, \([A \cdot R]\) the concentration of drug receptor complex, and \(K_A\) the equilibrium dissociation constant of the drug for the receptor. Implicit in Eq. 15 is the assumption that a single drug molecule binds to a single site on the receptor. Although this appears to be the case for many drug receptor interactions there are exceptions to this scheme. For example, two molecules of acetylcholine must bind to two apparently identical but cooperatively linked sites on a single nicotinic receptor in skeletal muscle to open the ion channel (580A). The concept of full and partial agonism was introduced by Ariens (20) in the form of a proportionality constant termed "intrinsic activity" (\(\alpha\)):

\[
\frac{E_A}{E_m} = \frac{\alpha [A \cdot R]}{[R_i]} = \frac{\alpha \cdot [A]}{[A] + K_A}
\]

where \(E_A\) and \(E_m\) refer to the response to a given concentration of \(A\) and the tissue maximal response, respectively. On the basis of the idea that response was not necessarily directly proportional to receptor occupancy, Stephenson (599) introduced the concept of stimulus (\(S\)) which assumed that response was some undefined function of stimulus:

\[
\frac{E_A}{E_m} = f(S)
\]

the requirements for the function being that it be monotonic and continuous. Thus responses in a given tissue could be produced by concentrations of two agonists that produced equal stimuli regardless of their relative receptor occupancy. The parameter that related stimulus to occupancy was termed "efficacy" (\(e\)):

\[
\frac{E_A}{E_m} = f\left(\frac{e \cdot [A]}{[A] + K_A}\right)
\]

Implicit in this hypothesis was the fact that, given a nonlinear relationship between stimulus and response, not all of the receptors need be occupied to produce the tissue maximal response.

As defined by Stephenson (599), efficacy was a drug and tissue dependent term. Furchgott (229) modified this model to differentiate the drug and the tissue factors of efficacy by defining intrinsic efficacy (\(\epsilon\)):

\[
e = \epsilon \cdot [R_i].
\]

In these terms intrinsic efficacy was strictly a drug-related parameter which should be constant for given drug receptor pairs across species and tissues (373). The various tissue and receptor-related factors of agonist response are defined in Eq. 20:

\[
\frac{E_A}{E_m} = f\left(\frac{\epsilon \cdot [R_i] \cdot [A]}{[A] + K_A}\right).
\]

Thus, the tissue-related factors are 1) \(f\), the function relating stimulus and response, and 2) the total receptor concentration (\([R_i]\)). The receptor-related factors are 1) \(K_A\), the equilibrium dissociation constant of the drug for the receptor, and 2) \(\epsilon\), the intrinsic efficacy. Insofar as the agonist may be removed from the receptor compartment by the tissue, \([A]\) may be influenced by tissue
factors but if meaningful drug receptor parameters are to be estimated, these influences must be minimized. The following analyses are all aimed at defining various constants describing solely drug receptor parameters by utilization of null methods which cancel the tissue factors. As a preface, a discussion of some of the factors relevant to the translation of receptor stimulus to tissue response is appropriate.

C. The Relationship between Stimulus and Response

The simplest relationship between receptor stimulus and tissue response is a linear one (direct relationship) and for some weak partial agonists this may be an accurate approximation (551). However, there is a wealth of evidence to suggest that in many isolated tissues the relationship between receptor occupancy (by the occupation model this is a direct function of stimulus) and tissue response is nonlinear. This has been proposed on theoretical grounds (599) and also is suggested by the fact that irreversible inactivation of a fraction of the available receptor pool can lead to dextral displacement of concentration-response curves to strong full agonists with no concomitant depression of the maximal response (27, 228, 229, 474, 673). This phenomenon is cited as evidence for "spare receptors" (receptor reserve, spare receptor capacity) in tissues, the rationale being that if an alkylating agent inactivates 99% of the viable receptors and the agonist still produces the tissue maximal response then 99% of the receptor population is "spare"; i.e., not required for the production of the maximal response. The term "receptor reserve" (spare receptors) is sometimes associated with tissues; e.g., the guinea pig ileum may be said to have a cholinergic receptor-reserve but, of course, this term cannot be applied generically to tissues but rather must be associated with a given agonist and tissue. Thus, the receptor reserve for two agonists in one tissue may be quite different.

Since the advent of pharmacological procedures to estimate the equilibrium dissociation constants of full agonists and the refinement of biochemical binding studies, quantitative evidence for nonlinear relationships between receptor occupancy and tissue response has accumulated. Table 5 shows examples of isolated tissues and drugs for which there is a disparity between the concentrations required for half maximal binding to receptors and those required for production of half maximal response. A plot of tissue response as a function of receptor occupancy for these full agonists (by the Langmuir adsorption isotherm) demonstrates a necessarily nonlinear function typically hyperbolic in shape [for example, see Besse and Furchgott (64)]. The steepness of this hyperbolic function reflects the efficiency of the stimulus-response mechanism in the tissue. It should not be assumed that for drugs that have no receptor reserve (partial agonists) the relationship between receptor occupancy and tissue response is linear. For some weak agonists a direct relationship is observed (387, 551) but for other partial agonists, a hyperbolic relationship can be demonstrated. This has been shown for oxymetazoline in rat aorta (551), normorphine in ileum from morphine tolerant guinea pigs (522) and pirbuterol and prenalterol in rat atria (383). There are two factors that determine the efficiency of the stimulus response mechanism in a tissue: the number of receptors and the nature of the functions which translate receptor stimulus into tissue response. It is worth considering these separately.

1. Tissue Response as a Function of Stimulus. Since stimulus is a linear function of intrinsic efficacy, receptor occupancy and receptor number, the function relating stimulus and response must produce the nonlinearity between receptor occupancy and response if such is observed. Amplifier systems are common in biological systems (25, 271, 541) and if one step in the amplifier system reaches saturation, then a spare capacity results. Such systems hold advantages since they allow amplification and alternative regulatory input (271). A successive series of nonlinear functions where the product of one saturable process becomes a substrate or catalyst for the next saturable process provides for a much more skewed relationship between receptor occupancy and response than any one of the individual processes (541). A well-known cascade of this type is the formation of glucose by β-adrenergic drugs. In this system an amplification factor of eight orders of magnitude can be achieved (271), thus demonstrating a striking disparity between receptor occupancy and tissue response (figure 7).

There have been several mathematical models put forth to describe the nonlinear relationships between hormone binding and biological response which focus on the coupling between receptor and effector subunits (58, 85, 229, 347, 356). An interesting model that centers on the sequential nature of the second messenger theory has been put forward by Strickland and Loeb (605). This model is based on the interaction of the hormone with the receptor leading to the generation of an intracellular intermediate which interacts with an intracellular receptor to generate a response. The interesting aspect of this model is the mathematical consequence that the equilibrium dissociation constant for the overall process \(K_{\text{Total}}\) must be lower in magnitude than the equilibrium dissociation constant of the hormone binding to the extracellular receptor \(K_d\). Thus (605):

\[
K_{\text{Total}} = \left(\frac{K}{K + a \cdot R_i}\right) \cdot K_d
\]  

(21)

where \(K\) is the equilibrium dissociation constant for the binding reaction between the intracellular mediator and intracellular receptor, \(a\) is a proportionality constant reflecting the size of the pool of intracellular mediator and \(R_i\) is the number of extracellular hormone receptors. It can be seen from Eq. 21 that the concentration-response curve for the overall process must lie to the left of the receptor occupancy curve along the concentration
<table>
<thead>
<tr>
<th>Receptor</th>
<th>Species</th>
<th>Tissue</th>
<th>Agonist</th>
<th>(-\log (EC_{50}))</th>
<th>(pK_a) Reserve</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Muscarinic</td>
<td>Guinea pig</td>
<td>Ileum</td>
<td>Acetylcholine</td>
<td>7.23</td>
<td>5.8–5.1</td>
<td>190–398 (560)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Carbachol</td>
<td>7.3–6.5</td>
<td>4.92</td>
<td>38–240 (236)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Pilocarpine</td>
<td>6.3</td>
<td>5.35–5.48</td>
<td>6.8–9 (235)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Left atrium</td>
<td>Carbachol</td>
<td>6.76</td>
<td>4.98</td>
<td>64 (229)</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Aorta</td>
<td></td>
<td>Carbachol</td>
<td>6.06</td>
<td>4.8</td>
<td>18 (229)</td>
</tr>
<tr>
<td></td>
<td>Stomach fundus</td>
<td>Carbachol</td>
<td>7.26</td>
<td>4.8</td>
<td>288</td>
<td>(229)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Rat</td>
<td>Anococcygeus muscle</td>
<td>Norepinephrine</td>
<td>7.5</td>
<td>6.3</td>
<td>16 (370)</td>
</tr>
<tr>
<td></td>
<td>Aorta</td>
<td></td>
<td>oxymetazoline</td>
<td>7.5</td>
<td>6.7</td>
<td>6.3 (377)</td>
</tr>
<tr>
<td>Papillary muscle</td>
<td>Ileum</td>
<td></td>
<td>l-Norepinephrine</td>
<td>7.9</td>
<td>6.47</td>
<td>21 (64)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>l-Epinephrine</td>
<td>7.92</td>
<td>6.69</td>
<td>17.2 (64)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>l-Phenylephrine</td>
<td>7.2</td>
<td>5.95</td>
<td>18.3 (64)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>oxymetazoline</td>
<td>6.74</td>
<td>5.9</td>
<td>7.0 (578)</td>
</tr>
<tr>
<td>Spleen</td>
<td></td>
<td>l-Norepinephrine</td>
<td>6.03</td>
<td>5.5</td>
<td>3.4</td>
<td>(580)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Epinephrine</td>
<td>5.83</td>
<td>4.2</td>
<td>27</td>
<td>(64)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Metaraminol</td>
<td>5.66</td>
<td>4.8</td>
<td>7.0</td>
<td>(578)</td>
</tr>
<tr>
<td>Spleen</td>
<td></td>
<td>l-Norepinephrine</td>
<td>5.49</td>
<td>4.8</td>
<td>5.0</td>
<td>(578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Epinephrine</td>
<td>7.37</td>
<td>6.13</td>
<td>17.3</td>
<td>(578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Phenylephrine</td>
<td>6.47</td>
<td>6.62</td>
<td>7.1</td>
<td>(578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Norepinephrine</td>
<td>5.62</td>
<td>4.87</td>
<td>5.6</td>
<td>(578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Epinephrine</td>
<td>6.47</td>
<td>3.89</td>
<td>3.8</td>
<td>(578)</td>
</tr>
<tr>
<td>Spleen</td>
<td></td>
<td>l-Norepinephrine</td>
<td>5.62</td>
<td>4.87</td>
<td>5.6</td>
<td>(578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Epinephrine</td>
<td>6.47</td>
<td>3.89</td>
<td>3.8</td>
<td>(578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Metaraminol</td>
<td>5.49</td>
<td>4.8</td>
<td>5.0</td>
<td>(578)</td>
</tr>
<tr>
<td>Spleen</td>
<td></td>
<td>l-Norepinephrine</td>
<td>7.37</td>
<td>6.13</td>
<td>17.3</td>
<td>(578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Epinephrine</td>
<td>6.47</td>
<td>6.62</td>
<td>7.1</td>
<td>(578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Phenylephrine</td>
<td>5.62</td>
<td>4.87</td>
<td>5.6</td>
<td>(578)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Norepinephrine</td>
<td>6.3</td>
<td>6.15–6.04</td>
<td>1.4–2</td>
<td>(235)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>l-Epinephrine</td>
<td>5.9</td>
<td>5.1</td>
<td>6.2</td>
<td>(612)</td>
</tr>
<tr>
<td>Mouse</td>
<td>Ileum</td>
<td></td>
<td>Methacholine</td>
<td>6.65</td>
<td>6.04</td>
<td>4 (612)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>oxotremorine</td>
<td>6.65</td>
<td>6.1</td>
<td>3 (612)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Bethanechol</td>
<td>5.45</td>
<td>4.6</td>
<td>7 (612)</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Ileum</td>
<td></td>
<td>Carbachol</td>
<td>6.67</td>
<td>4.37</td>
<td>155 (11)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Rat</td>
<td>Vas deferens</td>
<td>Norepinephrine</td>
<td>6.92</td>
<td>4.95</td>
<td>93 (456)</td>
</tr>
<tr>
<td></td>
<td>Carotid artery</td>
<td>Epinephrine</td>
<td>7.04</td>
<td>5.13</td>
<td>82</td>
<td>(456)</td>
</tr>
<tr>
<td></td>
<td>Carotid artery</td>
<td>Methoxamine</td>
<td>5.54</td>
<td>4.13</td>
<td>25</td>
<td>(612)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Rat</td>
<td>Cardiocytes</td>
<td>Phenylephrine</td>
<td>5.85</td>
<td>4.88</td>
<td>9.2 (456)</td>
</tr>
<tr>
<td></td>
<td>Rabbit</td>
<td>Detrusor muscle</td>
<td>Norepinephrine</td>
<td>6.92</td>
<td>4.95</td>
<td>93 (456)</td>
</tr>
<tr>
<td></td>
<td>Rabbit</td>
<td>Vas deferens</td>
<td>Epinephrine</td>
<td>7.04</td>
<td>5.13</td>
<td>82 (456)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Rat</td>
<td>Cardiocytes</td>
<td>Phenylephrine</td>
<td>5.85</td>
<td>4.88</td>
<td>9.2 (456)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Rat</td>
<td>Cardiocytes</td>
<td>Isoproterenol</td>
<td>7.06</td>
<td>6.1</td>
<td>9 (535)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Rat</td>
<td>Cardiocytes</td>
<td>Isoproterenol</td>
<td>8.43</td>
<td>6.96</td>
<td>295 (360)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Cat</td>
<td>Papillary muscle</td>
<td>Dichloroisoproterenol</td>
<td>7.82</td>
<td>7.59</td>
<td>1.7 (360)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Cat</td>
<td>Papillary muscle</td>
<td>Isoproterenol</td>
<td>9.1</td>
<td>6.7</td>
<td>251 (360)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Cat</td>
<td>Papillary muscle</td>
<td>Dichloroisoproterenol</td>
<td>6.7</td>
<td>6.2</td>
<td>3.2 (360)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Cat</td>
<td>Papillary muscle</td>
<td>Epinephrine</td>
<td>8.1</td>
<td>5.8</td>
<td>200 (360)</td>
</tr>
<tr>
<td>(\alpha)-Adrenergic</td>
<td>Cat</td>
<td>Papillary muscle</td>
<td>Norepinephrine</td>
<td>8.0</td>
<td>5.7</td>
<td>200 (360)</td>
</tr>
</tbody>
</table>

* Method of Furchgott (229).
† Defined as antilog \((-\log EC_{50} - pK_a\) or \(-pK_a\)).
‡ The affinity of many agonists in radioligand binding studies is dependent upon experimental conditions and it is not yet clear which affinity state is relevant to the pharmacological \(K_a\). Therefore, the reserves calculated may be substantially in error.
§ Potassium and rubidium efflux.
¶ Adenyl cyclase activity.
Epinephrine, Glucagon (and others)

1. Adenylate Cyclase INACTIVE

2. ATP

3. Protein Kinase INHIBITED

4. ATP

5. Phosphorylase Kinase INACTIVE

6. Phosphorylase Kinase - PO₄

Glucose

Glycogen

Glycolysis and Krebs' Cycle

Plasma

Fig. 7. The cascade of reactions involved in the production of glucose by β-adrenoceptor or glucagon stimulation. The amplification factor of 8 orders of magnitude can be expressed in the great difference between the binding curve for occupancy and response (inset). Reprinted with permission from Goldberg (271).
axis, the degree of shift depending upon the size of the pool of the intracellular messenger and number of hormone receptors.

In pharmacological systems, there are many examples of tissues that demonstrate hyperbolic functions between receptor occupancy and mechanisms which precede tissue response. For example, there is evidence to suggest nonlinear relationships between muscarinic receptor occupancy and calcium transport across cell membranes (11, 337, 338) and potassium efflux (109). A well-known example is the nonlinear relationship between \( \beta \)-adrenoceptor occupancy and adenyl cyclase activation. Thus, an "enzyme reserve" has been noted in postnatal rat hearts (360, 535) and kitten papillary muscle (359). There also are examples of nonlinear relationships between intermediate steps in the stimulus-response chain and tissue response. Thus, in many tissues, submaximal cyclic AMP production is associated with maximal tissue responses (121, 360, 572, 605). Lastly, the degree of cell-to-cell coupling may determine how much of the tissue must be activated for syncytial responses (69, 327, 672, 674). For example, experimental evidence suggests that isoproterenol need activate only a small fraction of the total muscle mass of cat papillary muscle for complete activation of the tissue (51, 327, 672, 674). In general, there are numerous examples of saturable nonlinear functions relating receptor occupancy and processes which in turn initiate events leading to tissue response. Often these events are multiple which can increase the amplification factor. Cell-to-cell amplification factors may further skew the nonlinear relationship between receptor occupancy and tissue response.

2. Receptor Density. The other tissue factor that determines the magnitude of the agonist response is the number of viable receptors in the tissue. From Eq. 20 it can be seen that the larger the number of receptors, the more agonist response should be obtained. This also is evident in the second messenger model by Strickland and Loeb (605; Eq. 21). There are examples of correlations between receptor density and hormonal response (121, 250, 342, 396, 438, 450). For example, the relative potency of oxotremorine on guinea pig and mouse ileum (8:1) correlates well with the number of muscarinic receptors estimated in binding studies [7.6:1 (647)]. Takeyasu and coworkers (612) have shown a loss of sensitivity of mouse and guinea pig ileum to cholinergic stimulation with dibenamine treatment which parallels the reduction in cholinergic receptors as measured by \(^{3}H\)-quinuclidinybenzilate binding. On the other hand, desensitization of rat atria by implantation of mini-osmotic pumps delivering isoproterenol produces a reduction in \( \beta \)-adrenoceptors that is not directly proportional to the decrease in the sensitivity of atria to isoproterenol (388). Correlations between receptor density and tissue sensitivity can be misleading. For example, mouse thymus has 4.6 times more \( \beta \)-adrenoceptors than mouse spleen but the spleen is 20 times more sensitive to isoproterenol (519).

V. Methods of Drug Receptor Classification

Theoretically there are numerous methods to classify drug receptors (73, 74). For example, receptors can be classified in terms of the different stimuli imparted to the stimulus-response mechanism of tissues (24). There could be further classification on the basis of chemical messenger (26). Another approach is classification by anatomical location, a well-known example being pre- and postsynaptic receptors. Another case of this type of differentiation is the relative innervation of \( \alpha \)- and \( \beta \)-adrenoceptors being associated with receptor subtypes (25, 26). As pointed out by Ariens and coworkers (24) these types of classification can lead to ambiguity; the recent discoveries of postsynaptic \( \alpha_{2} \)-adrenoceptors being an example where classification by location is unsatisfactory (629).

A theoretically more sound and experimentally more fruitful approach has been classification by pharmacological criteria (73). The null methods which are used in these procedures hopefully yield parameters for drugs and receptors that transcend function and location and have relevance to studies in man. There are four commonly used pharmacological methods of drug and drug receptor classification: 1) agonist potency ratios (rank order of potency); 2) selective agonism; 3) comparison of agonist affinity and relative intrinsic efficacy; 4) quantification of competitive antagonist affinity (pK\(_{A}\)).

It is worth considering each of these separately.

A. Agonist Potency Ratios

The relative potency of agonists has long been (41) and is still often used for receptor classification but a number of caveats should be made to this method. Firstly, the effects of uptake processes must be eliminated since selective uptake can produce serious errors in agonist potency ratios. For example, the selective potency of salbutamol over norepinephrine (20:1) is eliminated (0.9:1) in guinea pig trachea by cocaine inhibition of neuronal uptake (367). Leighton (415) has shown that rank order of potency as well as potency ratios can change in rat anococcygeus muscle after cocaine inhibition of neuronal uptake. Thus, a potency ratio of 50:1 for methoxamine over norepinephrine in this tissue was changed to 0.2:1 after cocaine (415).

The relative potency of full and partial agonists can vary capriciously from tissue to tissue because of variances in receptor number and the relative efficiency of stimulus response relationships. This is because differences in receptor coupling cause differences in the location parameters of concentration-response curves to full agonists (shifts along the concentration axis) but not partial agonists. Instead, differences in receptor coupling produce changes in the maximal responses to partial agonists but little displacement of the concentration-
response curves. Thus, in two different tissues with identical receptors but different stimulus-response characteristics, a full and a partial agonist may have different potency ratios [see figure 1 of Furchgott (232)]. Therefore, it is theoretically more sound to compare potency ratios of full agonists.

Assuming that the $K_A$ for full agonists significantly exceeds the concentrations required for response ($K_A \gg [A]$), then the stimulus to an agonist can be given by:

$$S = \varepsilon \cdot [R_t] \cdot [A]/K_A.$$ Therefore, in any single tissue ($[R]$ constant) the respective stimuli to agonists $A_1$ and $A_2$ is:

$$S_1 = \varepsilon_1[A_1]/K_{A1} \quad \text{and} \quad S_2 = \varepsilon_2[A_2]/K_{A2}. \quad (22)$$

The potency ratio $(pr)$ of these two full agonists in producing equal responses ($S_1 = S_2$) is:

$$pr = \frac{[A_1]}{[A_2]} = \frac{\varepsilon_2 \cdot K_{A1}}{\varepsilon_1 \cdot K_{A2}}. \quad (23)$$

As can be seen from Eq. 23, the potency ratio for two full agonists in a tissue (assuming an adequate receptor reserve) reflects only the drug receptor parameters $\varepsilon$ and $K_A$ and therefore is tissue independent. Under these circumstances, the potency ratio is a powerful quantitative constant for drug receptor classification. The importance of $pr$ as a quantity and not a qualitative statement of rank order of potency should be stressed. The rank order of potency is a crude and misleading parameter which has limited value in drug receptor classification. Agonists could have the same order of potency in different tissues but a different relative potency ratio. The quantitative data, namely the actual magnitudes of the potency ratios, would suggest that the receptors are different while the rank order would suggest identity of receptors. Assuming that $pr$ reflects relative $\varepsilon$ and $K_A$, the quantitative data would be correct.

A specialized approach related to agonist potency ratios is the use of optical isomers to classify receptors (517). Thus, the ratio of activities of two optical isomers of the same drug should be unique for a given receptor and yield an isomeric ratio for receptor classification purposes. The reader is referred to a comprehensive review by Patil and coworkers (504) on this method for further details.

**B. Selective Agonism**

Frequently, judgments are made about the presence or absence of a certain receptor in a tissue on the basis of the observation of the presence or absence of responses to a selective agonist (classified on some other tissue or tissues). There are two settings for these types of experiments. In one, the receptors of a new tissue, as yet unclassified, are subjected to trial by selective agonism. In the other, a given tissue, which responds to selective agonists, is modified either by receptor alkylation, receptor desensitization, or selective modification of stimulus-response characteristics and the resulting effects on the responses to the selective agonists are used for classification purposes. There are criteria to be met for either of these procedures to be successful from the point of view of unequivocal receptor classification.

In the first type of experiment the tissue either responds or does not respond to the selective agonist. If the tissue does not respond it means either that the receptors for the particular selective agonist are not present in the tissue or that the stimulus-response mechanism of the tissue produced insufficient amplification of the receptor stimulus to generate a response. An example of the latter was observed with prnalterol, a relatively weak $\beta_1$-adrenoceptor partial agonist shown to have affinity and efficacy for $\beta_2$-adrenoceptors (379). An apparent paradox was observed when prnalterol produced no agonist responses in canine coronary artery, a $\beta_2$-adrenoceptor-containing tissue (46, 464, 382). However, it was found that prnalterol proved to be a competitive antagonist of isoproterenol, a more powerful agonist in this tissue (382), and yielded a $pK_A$ consistent with $\beta_1$-adrenoceptor antagonism. These experiments showed that the canine coronary artery simply did not possess an adequately efficient stimulus-response mechanism to allow this weak $\beta_2$-adrenoceptor partial agonist to demonstrate a response.

If a selective agonist produces a response in a tissue then this constitutes circumstantial evidence that the receptor for which the agonist is selective is present in the tissue. However, a distinction should be made between selectivity and specificity. To assume that the selective agonist only has affinity and efficacy for one receptor is to confer upon it specificity. Pharmacological experience with drugs shows this to be the exception and not the rule. For example, the putative $\beta_1$-adrenoceptor selective agonists prnalterol, dobutamine, and tazolol all produce full agonist responses in rat uterus, a tissue generally thought to contain $\beta_2$-adrenoceptors. This observation leads to two possible conclusions: 1) the rat uterus contains previously undetected $\beta_1$-adrenoceptors, and 2) the putative $\beta_1$-adrenoceptor selective agonists have affinity and efficacy for $\beta_2$-adrenoceptors. Experiments with selective antagonists showed the second alternative to be true for rat uterus (375) and illustrates the importance of not assuming strict specificity for agonists.

Selective desensitization of responses to a certain agonist (47) or selective irreversible inhibition of responses by an alkylating agent have been techniques used to differentiate drug receptors in tissues. Coupled with the technique of selective alkylation is the selective protection of drug receptors by drugs during the alkylation process (227). However, these techniques have a major drawback is that they can give completely misleading information if the receptor reserves for the two agonists concerned are different. For example, if one agonist has
a 90% receptor reserve and another a 40% receptor reserve, then the responses to the latter agonist will be more sensitive to removal of portions of the receptor pool either by desensitization or alkylation. This point has been stressed for experiments with full and partial agonists (684) but can be extended to two full agonists as well. For example, consider the responses of rat anococcygeus muscle to oxymetazoline and norepinephrine (figure 8A). In control tissues, oxymetazoline is a slightly more potent agonist than norepinephrine (uptake blocked) but as the α-adrenoceptor population of the tissue is irreversibly inactivated by controlled exposure to the alkylating agent phenoxbenzamine, it can be seen from figure 8A that the responses to oxymetazoline, the more potent agonist, are disproportionately more depressed than those of norepinephrine (377). This is because the efficacy of norepinephrine is greater than that of oxymetazoline; this fact makes the maximal response to norepinephrine more resistant to decreases in receptor number than oxymetazoline. This latter agonist is more potent in untreated tissue because it has a higher affinity for α-adrenoceptors (377). In fact these agonists illustrate a general prediction from classical occupation theory namely that the maximal responses to agonists of high efficacy are less sensitive to decreases in receptor number or general efficiency of stimulus-response coupling than those of agonists of lower efficacy. Figure 8B shows a theoretical example of two agonists, A1 and A2; A1 has 5 times the affinity but only 0.2 times the efficacy of A2. The concentration-response curve to A2 (broken line) is more easily depressed by serial decreases in receptor number.

This principle can be extended to the effects of agonists in two different tissues differing in stimulus-response characteristics. It can be seen from figure 8C that oxymetazoline, an agonist with a higher affinity but lower efficacy for α-adrenoceptors than norepinephrine, is a more potent full agonist than norepinephrine in rat anococcygeus muscle, a tissue with an efficient stimulus-response apparatus. However in rat vas deferens, a tissue with a less efficient stimulus response mechanism, oxymetazoline is a weak partial agonist when compared to norepinephrine by virtue of its low intrinsic efficacy relative to norepinephrine. The profile of reversed agonist activities for these two drugs in rat anococcygeus muscle and vas deferens resembles receptor selectivity but, in these experiments, no evidence of heterogeneous α-adrenoceptor populations was found (377) and the theoretical calculations (figure 8B) show that none is required to explain the experimental results.

The theory and the data illustrate that receptor alkylation or desensitization will preferentially block the responses to the agonist with the lower intrinsic efficacy. Therefore, if two agonists produce responses in a tissue and alkylation or desensitization selectively eliminates the responses to one of the agonists, this need not imply that the two agonists activate separate receptors in the tissue.

The same caveat should be made regarding selective modulation of stimulus-response mechanisms in tissues. For example, recent evidence suggests that external calcium ion is required for the production of responses subserved by α2-adrenoceptors in contrast to α1-adrenoceptors which appear to use intracellular calcium stores (628, 656, 658, 659, 667). The evidence for this hypothesis is the disparately greater degree of antagonism of responses to putatively selective agonists for α2-adrenoceptors, compared to those of α1-adrenoceptors, produced by calcium entry inhibitors. The rationale, therefore, is that the responses to α2-adrenoceptors rely on the entry of extracellular calcium. It should be noted, however, that the selective α2-adrenoceptor agonists are partial agonists in these preparations while the α1-adrenoceptor agonists are full agonists leading to questions about sensitivity of these two types of agonist to differences in receptor reserves or receptor coupling. The hypotheses equating receptor type with calcium source rely on subjective assessments of antagonism of agonist; i.e., a given concentration of calcium antagonist may produce a small shift (1.5- to 2-fold) of the full α1-agonist and a 40% decrease in the maximal response to the partial α2-agonist. Unfortunately, the degree of maximal response depression of a partial agonist for a given shift to the right of a full agonist for a uniform modulation of receptor coupling is not known and, in fact, depends upon the nature of the stimulus response coupling. For example, a good estimation of experimental stimulus response curves can be obtained by the general logistic function of the form:

$$\frac{E_A}{E_m} = \frac{S^n}{S^n + \beta^n}$$  \hspace{1cm} (24)

where S is the stimulus, and β and n are fitting factors. With this model, a wide range of efficiencies of receptor coupling can be accommodated. Figure 9 shows the effects of a two-fold decrease in the efficiency of coupling in three tissues with different states of coupling (n = 1, 2, 3, Eq. 24). It can be seen from this figure that the degree of depression of maximal response to the partial agonist for a given shift to the right of the concentration-response curve to the full agonist is not constant. The important aspect of this calculation is the prediction that decreases in receptor number (i.e., receptor alkylation) should mimic the effects of calcium antagonists in these systems. However, the testing of the hypothesis with alkyllating agents requires care as to the selective alkylation of α1- or α2-adrenoceptors (147, 148) and obvious problems with usage of alkyllating agents in vivo (i.e., the pithed rat). A paper by Rimele and coworkers (539) suggests an alternative hypothesis, namely that the degree of dependence on activator calcium is not associated with receptor type as much as with the functional differ-
**Fig. 8.** The effects of changing receptor number on agonists with different ratios of efficacy and affinity. A. Experimental concentration-response curves in rat anococcygeus muscle. Ordinates: Response as a function of maximal control response. Abscissa: Logarithms of molar concentration of agonists. Responses to norepinephrine (●) and oxymetazoline (○) in untreated tissues (*n* = 6), treated with phenoxybenzamine 30 nM for 10 min (*n* = 6) and 0.1 μM for 10 min (*n* = 6). Bars represent S.E.M. B. Theoretical concentration-response curves to two agonists; broken line for agonist with 5 times the affinity but 0.2 times the efficacy of agonist designated by solid line. Abscissa: Logarithms of molar concentrations of agonists. Effects of a 100-fold decrease in receptor number ([R] = 1 to 0.01). C. Experimental concentration-response curves. Ordinates and abscissae as for part B. Responses of norepinephrine (●) and oxymetazoline (○) in rat anococcygeus muscle (*n* = 6) and rat vasa deferentia (*n* = 6). Bars represent S.E.M. Reprinted with permission from Kenakin (377).
C. Measurement of Agonist Affinity and Relative Efficacy

1. Agonist Affinity. Affinity is defined as the reciprocal of the equilibrium dissociation constant of the drug for the receptor \( K_A, \) Eq. 15). This parameter determines what fraction of the free receptors will be occupied by a given concentration of drug and thus defines the "... signal-to-noise ratio in the chemical cacophony which surrounds every cell" (74). There are null methods available to estimate this important drug constant.

The method of partial alkylation of receptors (229, 428, 430) is widely used to measure the equilibrium dissociation constant of a full agonist for a receptor. The basic premise of the method is that equiscient concentrations of agonist before and after irreversible elimination of a fraction of the drug receptors can be equated to yield differences that depend upon receptor number and agonist affinity. The mathematical manipulation of the equation allows cancellation of the receptor number term to yield an estimate of \( K_A \). The null nature of this method cancels effects of stimulus-response mechanisms but as originally described requires that the only difference in the tissue after treatment with alkylation agent is the number of viable drug receptors. Thus equiscient concentrations of a full agonist before \([A]\) and after \([A']\) partial alkylation of the receptor pool are compared in the following double reciprocal equation (229, 429, 430):

\[
\frac{1}{[A]} = \frac{1}{[A']} \cdot \frac{1}{q} + \frac{1}{K_A} \cdot \frac{(1 - q)}{q}
\]

(25)

where \( q \) is the fraction of viable receptors left in the tissue after alkylation. The \( K_A \) then can be calculated by:

\[
K_A = \frac{\text{Slope} - 1}{\text{Intercept}}
\]

(26)

There are methodological considerations to the effective use of this technique. For example, the concentration-response curve after receptor alkylation should have a depressed maximal response. Thron (626) has shown that values near to the top of the depressed concentration-response curve yield the best estimate of \( K_A \) with this method. While the linearization of the equations by a double reciprocal technique is convenient, Parker and Waud (498) have shown an improved fit of data points directly to the hyperbolic form of the relationship. Computer analysis has been applied to advantage with this technique as well (498, 714).

To use the method of partial receptor alkylation, as defined, an irreversible antagonist of the receptor is required. A useful group of drugs in this regard has been the \( \beta \)-haloalkylamines. Within this class are irreversible drugs for \( \alpha \)-adrenoceptors (227, 578, 609), cholinoreceptors (229, 257, 560), histamine \( H_1 \) receptors (227, 229, 386, 387), and serotonin receptors (227). These agents are convenient in that the noncycled chemical species can be chemically removed from the bathing medium by addition of a large excess of thiosulphate ion (226, 386, 377, 475) thereby stopping the alkylation process and allowing fine control of the procedure.

There are a number of other irreversible drugs available for drug receptors. The extreme chemical reactivity of azides has led to the development of photoaffinity labels for receptors. This approach theoretically can produce very selective irreversible drugs since they alkylate only after transformation to a highly reactive species (i.e., nitrile) upon irradiation with light (289, 582).
Thus, photoaffinity labels have been reported for β-adrenoceptors (304, 412, 557), histamine H₁ receptors (208, 209, 481), muscarinic receptors (391), adenosine receptors (208, 482), angiotensin receptors (203, 249), and dopamine receptors (345). The incorporation of 4'-amino-3',5'-diiodophenylalanine into peptides and subsequent conversion in situ to 4'-azidophenylalanine in theory makes possible the design of photoaffinity labels for many peptides (203). Other irreversible ligands include some toxins for muscarinic receptors (166) and halo-acetyl compounds for β-adrenoceptors [Ro 03-7894 (96, 473, 529, 701); bromoaacetylated alpenrolol (34); NHNP-NBE (31, 673)]. A thiadiazole, L-643,441, has been shown to irreversibly inhibit histamine H₂ receptors (43, 511, 639). Benextramine (BHC) is an irreversible inhibitor of α-adrenoceptors and muscarinic receptors (55) and α-chlornalxetamine irreversibly binds to opiate receptors (120, 524, 562). Some amino derivatives of strong analgesics also have been shown to irreversibly bind to opiate receptors (537). A unique approach has been the incorporation of multiple pharmacophores into molecules to produce drugs with essentially irreversible kinetics (518).

Given the variety of irreversible antagonists the method of partial receptor alkylation has been applied to numerous receptor types including β-adrenoceptors (580, 701), α-adrenoceptors (64, 346, 370, 377, 578, 714), histamine H₁ receptors (43, 229), histamine H₂ receptors (43), muscarinic receptors (229, 238, 257, 497, 540, 560, 612), and opiate receptors (522).

Although this method was designed for use with irreversible receptor antagonists, other methods to alter the stimulus response characteristics of tissues have been applied. For example, functional antagonism of responses to full agonists has been utilized to estimate \( K_A \) values for full agonists (105, 106, 704). Functional antagonism can be achieved either by addition of a drug which by an action on some other receptor produces a stimulus that opposes the primary stimulus or by a drug which in some way modulates the primary stimulus as it is converted into tissue response. There are a number of cautions to be made to the use of functional antagonism with this method. The primary rationale is that functional antagonism produces effects on the concentration-response curves to full agonists which closely resemble the effects of alkylating agents. However, functional antagonism is a very complex phenomenon (198, 433, 652, 653) and there is no theoretical basis for its application to the partial receptor alkylation technique. Comparisons of equal tissue state as opposed to equal responses should be utilized (433). Thus, if a spasmoden is used to physiologically antagonize a relaxant in a tissue, the concentration-response curves to the relaxant should not first be “normalized” (i.e., percent maximum) and then compared. Rather, relaxant doses producing equivalent contractile states (i.e., actual tension) should be used.

There have been relatively few quantitative comparisons made of \( K_A \) estimates by partial alkylation and by functional antagonism. Those studies which have been done have yielded mixed results. For example, Siegl and McNiel (580) found in rabbit papillary muscle that the estimates of \( K_A \) for phenylephrine acting on α-adrenoceptors made by partial alkylation of receptors (with dibenamine) agreed with estimates made by functional antagonism with the calcium channel antagonist D-600. However, the estimates for the \( K_A \) of isoproterenol with the alkylation agent (Ro 3-7894) and D-600 were quite different. In rabbit aorta, Hurwitz and coworkers (337) estimated the \( K_A \) for norepinephrine in rabbit aorta by comparing concentration-response curves in the presence of varying concentrations of calcium and obtained an estimate very similar to one by Besse and Furchgott (64) who used dibenamine as an alkylating agent. However, the calcium technique yielded a \( K_A \) for acetylcholine in guinea pig ileum longitudinal smooth muscle which was much lower (337) than that obtained by alkylation of receptors (538, 560). Recently, Leighton and Su (416) have used functional antagonism to calculate \( K_A \) values for presynaptic α-adrenoceptors. By altering extracellular calcium concentration or transmural stimulus conditions, clonidine was converted from a full to a partial agonist. Estimates of \( K_A \) values for clonidine made by these methods were not significantly different from those obtained by the receptor alkylation method. Theoretical analyses (198, 433) indicate that functional antagonism possibly might be suitable for estimation of \( K_A \) for agonists of low efficacy but not those of high efficacy. Experimental support for this idea was obtained in guinea pig left atria where the \( K_A \) estimated by functional antagonism and by receptor alkylation agreed quite well for the low efficacy muscarinic agonist pentytrimethylammonium but not so well for furthide and oxotremorine, agonists of higher intrinsic efficacy (198).

A novel method of obtaining \( K_A \) for an agonist is by application of perturbation techniques. In this method, some variable is changed suddenly and the kinetics of return to or relaxation to (hence the term, relaxation method) equilibrium are observed. The perturbation can be a change in concentration, membrane potential, temperature, or irradiation. The disturbing influence should produce a sudden change in a steady-state response \((\Delta r)\) to some agonist \([A]\). A time constant \((r)\), the time required for the response to recover to 0.37 times the original response, is recorded. This time constant is related to the kinetics of agonist binding by:

\[
\frac{1}{r} = k_1 [A] + k_2
\]

where \( k_1 \) and \( k_2 \) are the rates of onset and offset of the agonist. Thus, the repetition of this process at a number
of agonist concentrations furnishes data for a regression of 1/r upon [A] and \( K_A = k_0/k_1 = \text{intercept} + \text{slope} \). There are several caveats to be made for the use of this technique in pharmacological experiments (144). Diffusion must be shown not to be rate-limiting and the perturbation must only disturb the equilibrium between drug and receptor and not any of the processes in the stimulus-response chain for the method to yield valid estimates of \( K_A \). An intriguing approach by Lester (419) utilized a light activated agonist and rapidly changed the concentration of the agonist with brief flashes of light. Ultraviolet radiation has been used as a perturbing influence in pharmacological experiments in rabbit aortae (346, 614, 616, 617).

When dealing with partial agonists, the preceding and other methods can be utilized to measure the \( K_A \) as well but there are certain specialized procedures available for the estimation of the equilibrium dissociation constant of these drugs. Two important methods utilize comparisons of concentration-response curves to a full and a partial agonist in the same tissue. Both methods assume that the concentrations of full agonist needed to produce submaximal responses are much less than the \( K_A \). Under these circumstances equiactive concentrations of full and partial agonist can be equated by (44, specifically, the relationship between stimulus and response in the tissue introduces an error factor of unknown magnitude into the calculation if the relationship is not one-to-one (350): Specifically, the relationship between stimulus and response in the tissue introduces an error factor of unknown magnitude into the calculation if the relationship is not one-to-one (350). For example, if the tissue response is a rectangular hyperbolic function of stimulus, then the intercept of the Schild regression yields the logarithm of the \( K_p \) modified by a term which depends upon the relative efficacy of the full and partial agonist (350):

\[
\text{Intercept} = \log K_P (1 - \alpha)^{-1}
\]

where \( \alpha \) is the intrinsic activity (20) of the partial agonist. Clearly, if \( \epsilon_A \gg \epsilon_P \), this error will be negligible but not so if the partial agonist produces a sizeable response (high \( \epsilon_P \)). In these cases, techniques have been developed to eliminate the responses to the partial agonist so that the \( K_P \) may be estimated unambiguously by the Schild method. Owing to the fact that partial agonists have no receptor reserve and that irreversible alkylation of a portion of the receptors depresses the maximal responses to partial agonists (27, 665), one method available is the controlled alkylation of a portion of the receptors such that the responses to the partial agonist are eliminated and those to the full agonist are not. Under these circumstances, the partial agonist may be utilized as a competitive antagonist and the \( K_P \) estimated by Schild analysis (238, 370, 377, 498, 688). A variant of this method is the use of physiological antagonism to eliminate the agonist responses to the partial agonist (105, 106, 379).

A method which will yield the \( K_P \) of a partial agonist by comparison of concentration-response curves of a full (it need not be assumed that \( [A] \ll K_A \) and a partial agonist, providing that the \( K_A \) of the agonist is known,

\[
K_P = \frac{[P] \cdot \text{Slope}}{1 - \text{Slope}}
\]

If \( [A] \ll K_A \), then an error term is introduced into the estimate (385, 429, 430):

\[
K_P = \frac{[P] \cdot \text{Slope}}{1 - \text{Slope}} \left( 1 - \frac{\epsilon_P}{\epsilon_A} \right)
\]
has been proposed by Gero and Tallarida (254). If equiactive concentrations of full \([A_1]\) and partial \([P_1]\) agonists are determined along with the concentration of full agonist which is equiactive to the maximal response to the partial agonist \([A_P]\), then (254):

\[
K_P = \frac{K_A ([A_P] - [A_1]) [P_1]}{[A_1] ([A_P] + K_A)}.
\]

(35)

2. Agonist Efficacy. Some drugs bind to receptors and produce a tissue response while others produce no agonist response; the differentiating factor between these two drugs is that the former is said to possess intrinsic efficacy while the latter does not. This property of drugs which enables some drugs to “sit at the piano and play . . .” while others only sit (23A) has evoked much interest in pharmacology.

Because competitive antagonists produce no agonist responses, they are often said to possess no intrinsic efficacy. This is a theoretical concept, however, which disregards the limitations in the sensitivity of our systems to detect efficacy. For example, the well-known competitive antagonists propranolol and phenolamine both generate agonist responses in a primary cell culture of neonatal rat ventricle (310). These cells are 100 times more sensitive than intact neonatal rat hearts to \(\alpha\)- and \(\beta\)-adrenoceptor agonists, a hypersensitivity presumably due to extraordinarily efficient receptor coupling. It may be that all drugs possess affinity and efficacy and that our tissue systems for detecting efficacy can be thought to possess windows with thresholds of detection for this property of drugs.

The mathematical functions to express efficacy have been given in a previous section of this review where it should be noted that, in terms of occupation theory, efficacy is an empirical proportionality constant the magnitude of which has no implications as to mechanism of response production. Nevertheless, there are drug receptor models that describe efficacy in molecular terms. Efficacy is most often thought of as being the ability of a drug to produce a protein conformational change by, for example, causing the drug receptor protein to take on a lower free energy (“conformational induction”) (107). Drugs can be efficacious by completing the active site of an enzyme in the case of certain polypeptide hormones (549) or by allosteric generation of an active site in an enzyme (24). The two-state model describes the efficacy of a drug as its relative affinity for the active and inactive state of the receptor (“conformational selection”) (107, 125, 357).

An operational model of efficacy has recently been presented by Black and Leff (77) in which the receptor is considered to have cognitive and transitive properties. Thus, the binding of drug to the receptor is followed by the binding of the complex to an effector, a model similar in mathematical formulation to the floating receptor model (347, 610, 637) or the ternary complex model (176). In these models the fluidity of the lipid matrix (84, 85, 341, 550, 581) and the hydrophobicity of the receptor complex (161, 280, 348) would affect intrinsic efficacy. In the Black and Leff (77) model, efficacy would be defined as \([R_1]/K_E\) where \([R_1]\) is the concentration of receptors and \(K_E\) the equilibrium dissociation constant of the drug receptor complex and the effector unit.

Mechanistic considerations need not be a hindrance to the use of quantitative estimates of relative efficacy for drug and drug receptor classification. Null methods have been described which enable estimates to be made of the relative intrinsic efficacy of two agonists. These measurements must be of the relative efficacy of two agonists since presently there is no absolute independent scale of efficacy. Attempts have been made to define the absolute efficacy of agonists in terms of Stephenson’s (599) original formulation, namely that \(e\) equals unity at the reciprocal of the fractional receptor occupancy at 50% maximal response (253). However, this method cannot be used as a scale of intrinsic efficacy for the classification of agonists since it is tissue and not receptor-dependent. Therefore agonists will have a different efficacy for every tissue in keeping with Stephenson’s (599) formulation of efficacy but no so in terms of Furchgott’s (229) concept of intrinsic efficacy. The latter but not the former term is drug-receptor related and therefore of value in drug-receptor classification.

The relative efficacy of two agonists can be estimated by comparison of their respective concentration response curves (429, 430). A double reciprocal relationship between equiactive concentrations of agonists \([A_1]\) and \([A_2]\) yields a measure of the relative order of efficacy of the agonists:

\[
\frac{1}{[A_1]} = \frac{1}{[A_2]} \cdot \left(\frac{K_2}{K_1} \cdot \frac{e_1}{e_2}\right) + \frac{1}{e_2} \cdot \frac{1}{K_1} \left(1 - \frac{e_2}{e_1}\right).
\]

(36)

The arithmetic sign of the intercept indicates the relative order of the intrinsic efficacy of the agonists; if \(e_2 > e_1\) the intercept will be positive and if \(e_2 < e_1\) it will be negative (429, 430). A technical difficulty related to the effective use of this method occurs when the concentration-response curves are parallel causing the intercept to tend toward unity. Providing \(K_A\) for one of the agonists is known, a numerical estimate of the relative efficacy of the agonists can be calculated from (429, 430, 553):

\[
\frac{e_2}{e_1} = (1 + \text{Intercept} \cdot K_A)^{-1}.
\]

(37)

Furchgott (229) has described a widely used method of estimating the relative efficacy of two agonists. Considering two agonists which give equal stimuli \((S_1, S_2)\) to a tissue such that \(S_1 = e_1 \cdot p_1 \cdot [R_1]\) and \(S_2 = e_2 \cdot p_2 \cdot [R_2]\) where \(p\) is the fractional receptor occupancy, then (229):

\[
\frac{p_1}{p_2} = \frac{e_2}{e_1}.
\]

(38)
The responses to the two agonists are expressed as functions of \( \log \rho \) and the displacement between the curves on the abscissa scale equals the logarithm of the relative efficacy of the two agonists [e.g., figure 4 of Furchgott and Bursztyn (238); figure 4 of Kenakin (370)].

3. Experimental Manipulation of Receptor Number and Efficiency of Stimulus-Response Coupling. Clearly, an estimate of the efficacy of an agonist cannot be made in an isolated tissue unless the agonist produces a response in that tissue. Also, with the methods currently available, an unambiguous estimate of the affinity of the agonist is required for the estimation of efficacy. Unfortunately, the production of an agonist response by a drug often hampers the estimation of the affinity of that drug for the receptor. Under these circumstances it is advantageous to control the magnitude of response to an agonist in a tissue so that estimates of affinity and efficacy can be made independently. This is most easily done with agonists of low intrinsic efficacy.

Before discussion of interventions that can control the mechanisms for response in given isolated tissues, a related approach will be considered. This is the analysis of drug receptor parameters in tissues differing in stimulus-response characteristics but shown by other methods to have a homogeneous receptor population with respect to each other. Basically, in this analysis the agonist with the lower intrinsic efficacy is utilized as an antagonist of the agonist with higher intrinsic efficacy in tissues with poorly coupled receptors, and the resulting estimate of \( K_A \) used to calculate relative efficacy in tissues with the more efficient receptor coupling. This approach is based on the fact that the maximal responses to agonists of lower efficacy are more subject to the efficiency of receptor coupling than agonists of higher efficacy (i.e., see figure 8A). Therefore, in a series of tissues with progressively less efficient receptor coupling, the potency of the full agonist should decrease (increasing EC50) and the maximal response to a partial agonist should decrease correspondingly. The exact relationship between the maximal response to the partial agonist in a tissue with a given sensitivity to a full agonist depends upon the actual nature of the coupling (e.g., figure 9) but some good correlations between sensitivity of tissues to full agonists and maximal responses to partial agonists can be found. For example, figure 10A shows the range of sensitivities of tissues, all containing \( \beta_1 \)-adrenoceptors, to (-)-isoproterenol while figure 10B shows the corresponding concentration-response curves to the partial agonist prenalterol. Isoproterenol has 220 times the intrinsic efficacy of prenalterol (379) and, as predicted by classical receptor theory, the maximal responses to the drug with the lower intrinsic efficacy are depressed by reductions in the efficiency of coupling of receptors while the location parameters of the drug with the higher efficacy are displaced to the right. Figure 10C shows the correlation between sensitivity of these tissues to isoproterenol and the maximal response to prenalterol (379, 381). Similar results have been reported by Mattsson and coworkers (444). Figure 10D shows the wide range of efficiencies of receptor coupling in some \( \beta_1 \)-adrenoceptor-containing tissues and highlights the choices of tissues available for this type of approach. Such correlations would be predicted for full and partial agonists for all receptors. A similar relationship between the sensitivity of tissues to oxotremorine and the maximal responses to pilocarpine, full and partial agonists for cholinergic receptors, respectively, can be calculated (712).

The data in figures 10A and 10B shows the importance of receptor coupling for agonists of low intrinsic efficacy; even though both the rat right atria and canine coronary artery have \( \beta_1 \)-adrenoceptors, the former tissue responds both to isoproterenol and prenalterol while the latter tissue produces responses only to isoproterenol. The tissue selectivity of prenalterol does not depend upon receptor selectivity in these tissues (379, 381). Assuming identity of receptors across the tissue types, an unambiguous estimate of the affinity of prenalterol can be made in canine coronary artery (by the Schild method) and applied to any of tissues, which respond to prenalterol, in measurements of relative efficacy.

Differences other than inherent stimulus-response relationships between tissues can be exploited to control the sensitivity of tissues to full agonists and the maximal responses to partial agonists. In previous sections of this review, it was shown how differences in tissue sensitivity to agonists could be determined by the age of the animal or the anatomical location of the tissue preparation. An example of the latter is the differences in sensitivity of various parts of the urinary bladder to \( \beta \)- and \( \alpha \)-adrenoceptor agonists. Thus, Levin and Wein (421) have shown that methoxamine produces a 40% maximal response in the bladder body and 100% maximal response in the bladder base. Another determinant of sensitivity may be the method of measurement of responses. As noted earlier, the sensitivity of some tissues to cholinergic agonists is greater when the measurements are made isotonically rather than isometrically. Thus, in the frog rectus abdominus, carbachol is a full agonist for production of both isotonic and isometric responses, but with a larger contractile (receptor) reserve, as measured by receptor alkylation, under conditions of isotonic recording (451).

In general, these approaches introduce uncontrolled variables into the comparisons (i.e., species, tissue type) and theoretically are less sound than the modification of tissue stimulus-response characteristics to make the measurements of affinity and efficacy in the same tissue. The two tissue-related determinants of agonist response, namely receptor number and the efficiency of the mechanisms which convert receptor stimulus into response, are the primary targets for this type of experiment. As a
fig. 10. Relationships between tissue responses to full and partial agonists. A. Concentration-response curves of tissues to l-isoproterenol. Ordinates: Fractions of maximal responses to l-isoproterenol. Abscissae: Logarithms of molar concentrations of l-isoproterenol. Responses in thyroxine-treated guinea pig right atria (♀, n = 4), cat left atria (♂, n = 6), rat left atria (Δ, n = 8), cat papillary muscle (∆, n = 6), guinea pig left atria (□, n = 5) and dog coronary artery (■, n = 4). B. Responses of same tissues to prenalterol. Ordinates as for part A. Abscissae: Logarithms of molar concentrations of prenalterol. Values for n as for part A; bars represent S.E.M. Redrawn from Kenakin and Beck (379, 382). C. Maximal responses of tissues to prenalterol (as a fraction of the maximal response to isoproterenol) as a function of the sensitivity of the tissues to l-isoproterenol (expressed as the logarithm of the molar concentration of isoproterenol which produces half the maximal response). Data from parts A and B. D. Tissue responses of tissues to isoproterenol (as fractions of the maximal responses) as functions of the receptor occupancy of isoproterenol (calculated by the Langmuir isotherm assuming a homogeneous $K_d$ of 0.2 μM).

Preface to discussion of modifying stimulus-response characteristics of tissues, the need for appropriate controls should be stressed. The numerous interventions which affect responsiveness may or may not affect the nature of the drug receptors, thus experiments with competitive antagonists before and after intervention would be required. Schind analysis to indicate possible significant differences in the pKp for a range of agonists before and after intervention would be a useful check of receptor identity in these procedures.

A. THE MANIPULATION OF RECEPTOR NUMBER. Receptor number either can be modified chemically in vitro or with procedures which utilize the cells' own mechanisms for control of receptor number in vivo. The most widely used in vitro modification of drug receptor number is treatment of tissues with receptor alkylating agents. As discussed in the section on affinity, such treatments preferentially depress the maximal responses to partial agonists (27, 665) allowing them to be utilized as competitive antagonists.

The cellular control of receptor number has become relevant to human disease states (19, 37, 113, 149, 162, 348), drug tolerance (146, 224, 493), drug withdrawal (142, 526, 528), and aging (404-406, 678), and a number of chronic stimuli are capable of producing alteration of receptor number in laboratory animals. For example, the implantation of osmotic mini pumps delivering 400 μg kg⁻¹ h⁻¹ of l-isoproterenol was shown to decrease the number of β-adrenoceptors in rat myocardium (123, 124, 388) and correspondingly to shift the concentration-
response curve in rat atria to isoproteanol to the right and completely depress the maximal responses to the partial agonists prenalterol and pirbuterol (388) (figure 11A). In desensitized rats these drugs produced no agonist responses and therefore estimates of affinity for β-adrenoceptors were made by the Schild method (figure 11B). This then allowed for an estimate of the relative efficacy of these drugs by the method of Furchgott (229); see Eq. (38) in normal atria (383). Some common methods of decreasing receptor number involve chronic treatment with drugs either by repeated injection, implantation of mini osmotic pumps or pellets, or changes in the hormonal status of animals (i.e., thyroid state). Some examples of treatments for decreasing the number of receptors in various isolated tissues is given in table 6.

Increases in receptor number also can be utilized in measurements of drug receptor parameters. For example, in a poorly coupled tissue, the affinity of a weak partial agonist, which produces no agonist response, could be estimated by the Schild method. Treatment of the animal with procedures which promote receptor proliferation would produce sensitization to full agonists and may produce a tissue which demonstrates an agonist response to the partial agonist. This concentration-response curve then could be utilized for efficacy measurements. Some interventions which have been shown to increase receptor number are given in table 7.

B. MANIPULATION OF THE EFFICIENCY OF STIMULUS-RESPONSE COUPLING. If the receptor could be though of, in electronic terms, as the preamplifier then the stimulus-response machinery of the tissues is the power amplifier which converts the pre-amp signal (receptor stimulus) into the response. There are numerous ways of adjusting the level of the power amplifier. When doing this type of experiment, care must be taken to see that the receptor profile of the tissue is not altered. Thus, control experiments with full agonists and competitive antagonists should always be done before and after the interventions which modify tissue responsiveness to test for changes in receptors by Schild analysis.

Functional (physiological) antagonism of agonist responses has often been used to depress the maximal responses of partial agonists for Schild analysis. This technique is especially useful in tissues in which a drug is needed to induce a given pharmacological tone for agonist responses to be observed. For example, guinea pig trachea requires some other intrinsic or pharmacological tone in order for relaxant responses to be studied. The degree of tone in this tissue greatly modifies the location of concentration-response curves to relaxants (105, 106, 484). Other methods of modulating agonist responses involve specific cations. For instance, Burgen and Spero (110) found that the sensitivity of guinea pig ileum was greatly dependent upon calcium and/or magnesium ion. Takeyasu and coworkers (612) found that reduction of calcium ion makes pilocarpine, normally a full agonist in guinea pig ileum, into a partial agonist. The differential utilization of calcium by blood vessels makes adjustment of calcium concentration a powerful method of adjusting the sensitivity of blood vessels to contractile agonists (329, 448). Tissue sensitivity to agonists can be decreased by a number of in vivo treatments. Table 8 lists some methods used to decrease tissue sensitivity to agonists; it should be noted that many of these treatments may decrease receptor number as a mechanism of action but since binding data corroborating this is not given in these papers, the effects will be referred to as a general decrease in sensitivity.

Potentiation of responses can occur by augmentation of some step or the inhibition of some modulatory influence in the stimulus-response chain. An example of this latter mechanism is the inhibition of phosphodiesterase to potentiate the effects of drugs which increase cellular cyclic AMP. It is well known that inhibition of this enzyme produces sinistral displacement of concentra-
### Methods to decrease receptor number

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>Receptor</th>
<th>Response</th>
<th>Method</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Heart</td>
<td>(\beta)</td>
<td>(\downarrow)</td>
<td>Chronic isoproterenol (478)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(\downarrow)</td>
<td>Chronic isoproterenol (388)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Low dose propranolol (33)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Hypothyroid state (36, 129, 700)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Deoxycorticosterone and salt, renal hypertensive</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Training (611)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Alloxan-induced diabetes (340)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>(\alpha)</td>
<td>(\downarrow)</td>
<td>Chronic desmethyli mipramine (696)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lung</td>
<td>ACh</td>
<td>(\downarrow)</td>
<td>Hypothyroid state (574)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Thyroidectomy (32)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Vasa</td>
<td>(\alpha)</td>
<td></td>
<td>Chronic metaproterenol (563)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Lung</td>
<td>ACh</td>
<td></td>
<td>Thyroidectomy (32)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Uterus</td>
<td>(\beta)</td>
<td>(\downarrow)</td>
<td>Chronic isoproterenol (352)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Soleus</td>
<td>(\beta)</td>
<td></td>
<td>Chronic isoproterenol (651)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tibialis</td>
<td>(\beta)</td>
<td></td>
<td>Chronic isoproterenol (651)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Submaxillary gland</td>
<td>ACh</td>
<td>(\downarrow)</td>
<td>Hypothyroid state (574)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Submaxillary gland</td>
<td>(\beta)</td>
<td></td>
<td>Hypothyroid state (520)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Renal cortex</td>
<td>(\beta)</td>
<td></td>
<td>Implant pheochromocytoma (590)</td>
<td></td>
</tr>
<tr>
<td>Guineas pig</td>
<td>Lung</td>
<td>(\beta)</td>
<td>(\downarrow)</td>
<td><em>Haemophilus influenzae</em> virus (569)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(\downarrow)</td>
<td>Chronic desmethyli mipramine (569)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Ileum</td>
<td>ACh</td>
<td></td>
<td>Bacterial infection (570)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Urinary bladder</td>
<td>ACh</td>
<td></td>
<td>Chronic diisopropyl phosphorofluoridate (708)</td>
<td></td>
</tr>
<tr>
<td>Frog</td>
<td>Erythrocyte</td>
<td>(\beta)</td>
<td>(\downarrow)</td>
<td>In vitro isoproterenol (452, 694)</td>
<td></td>
</tr>
<tr>
<td>Mouse</td>
<td>Small intestine</td>
<td>ACh</td>
<td>(\downarrow)</td>
<td>Chronic diisopropyl phosphorofluoridate (647)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(\downarrow)</td>
<td>Cold stress (648)</td>
<td></td>
</tr>
</tbody>
</table>

* \(\beta\), \(\beta\)-adrenergic; \(\alpha\), \(\alpha\)-adrenergic; ACh, acetylcholine.

† ‡, Decreased response; † ‡, response not tested.

---

The concentration-response curves to full agonists and theoretical considerations would predict increases in the maximal responses to partial agonists. This effect was used to measure the relative efficacy of drugs in guinea pig papillary muscle. In this tissue, prenalterol does not produce an agonist response and can be used as a competitive antagonist of responses to l-isoproterenol. The phosphodiesterase inhibitor, isobutylmethylxanthine, generates a shift to the left of the concentration-response curve to isoproterenol and produces a tissue in which prenalterol demonstrates a concentration-response curve. The estimate of affinity from the normal tissue and agonist responses from sensitized tissue allow for an estimate of relative efficacy to be made (384). The potentiation may be brought about chemically as, for example, the potentiation of agonist response in arterial tissues produced by sulphydryl reagents (29). Chronic treatments can produce supersensitivity in tissues by receptor proliferation but also by other means (217). Thus, chronic reserpine treatment selectively potentiates responses of rabbit aorta to norepinephrine, phenylephrine, acetylcholine, and potassium but not serotonin, histamine, or angiotensin (328, 621). These effects, termed nondeviational supersensitivity by Fleming (216), can involve changes in calcium binding or flux, partial depolarization of tissues or the increase of tight junctions between muscle cells. Table 9 lists some treatments that have been found to produce supersensitivity in tissues. As with table 8, receptor number was not studied biochemically thus it is not known whether the effects are due to receptor number or to some other factor.
TABLE 7

Methods to increase receptor number

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>Receptor</th>
<th>Response†</th>
<th>Method</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Heart</td>
<td>β</td>
<td>—</td>
<td>Chronic guanethidine</td>
<td>(265)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chronic propranolol</td>
<td>(264)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>(injection)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chronic propranolol (mini-pump)</td>
<td>(1)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Isoproterenol, —</td>
<td>6-Hydroxydopamine (neonatally)</td>
<td>(476)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Norepinephrine, ↑</td>
<td>Hyperthyroid state</td>
<td>(700)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>ACh</td>
<td>Hypothyroid state</td>
<td>(574)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>↑</td>
<td>Chronic isoproterenol</td>
<td>(478)</td>
</tr>
<tr>
<td>Lung</td>
<td></td>
<td>β</td>
<td>—</td>
<td>Chronic propranolol (mini-pump)</td>
<td>(1)</td>
</tr>
<tr>
<td>Salivary gland</td>
<td>ACh, VIP</td>
<td>↑, ↑</td>
<td></td>
<td>Chronic atropine</td>
<td>(307)</td>
</tr>
<tr>
<td>Submaxillary gland</td>
<td>ACh</td>
<td></td>
<td></td>
<td>Hypothyroid state</td>
<td>(520)</td>
</tr>
<tr>
<td>Lymphocyte</td>
<td>β</td>
<td></td>
<td></td>
<td>Hyperthyroid state</td>
<td>(520)</td>
</tr>
<tr>
<td>Vas deferens</td>
<td>α</td>
<td></td>
<td>Chronic propranolol</td>
<td>(1)</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Chronic prazosin</td>
<td>(698)</td>
</tr>
<tr>
<td>Cat</td>
<td>Superior cervical ganglion</td>
<td>ACh</td>
<td>—</td>
<td>Denervation</td>
<td>(618)</td>
</tr>
<tr>
<td>Mouse</td>
<td>Small intestine</td>
<td>ACh</td>
<td>↑</td>
<td>Chronic hexamethonium</td>
<td>(649)</td>
</tr>
</tbody>
</table>

* β, β-adrenergic; ACh, acetylcholine; VIP, vasoactive intestinal peptide; α, α-adrenergic.
†, †↑, Increased response; — response not tested.

TABLE 8

Methods to decrease tissue sensitivity to agonists

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>Receptor</th>
<th>Method</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Atria</td>
<td>β</td>
<td>Immobilization stress</td>
<td>(710)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ACh</td>
<td>Hyperthyroid state</td>
<td>(343)</td>
</tr>
<tr>
<td>Aorta</td>
<td></td>
<td>β</td>
<td>Chronic isoproterenol</td>
<td>(608)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>α</td>
<td>Chronic phenylephrine (mini-pump)</td>
<td>(608)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chronic propranolol</td>
<td>(623)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>and withdrawal</td>
<td></td>
</tr>
<tr>
<td>Uterus</td>
<td>β</td>
<td></td>
<td>Restricted diet</td>
<td>(600)</td>
</tr>
<tr>
<td>Fat cells</td>
<td>β</td>
<td></td>
<td>Chronic salbutamol</td>
<td>(224)</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Atria</td>
<td>β</td>
<td>In vitro isoproterenol</td>
<td>(381)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(353)</td>
<td></td>
</tr>
<tr>
<td>Ileum</td>
<td></td>
<td>β</td>
<td>In vitro morphine</td>
<td>(536)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Subcutaneous morphine pellets</td>
<td>(273, 522)</td>
</tr>
<tr>
<td>Soleus muscle</td>
<td>β</td>
<td></td>
<td>Terbutaline in food</td>
<td>(322)</td>
</tr>
<tr>
<td>Extensor digitorum longus muscle</td>
<td>β</td>
<td></td>
<td>Terbutaline in food</td>
<td>(322)</td>
</tr>
</tbody>
</table>

* β, β-adrenergic; ACh, acetylcholine; α, α-adrenergic.

D. Competitive Antagonism

1. The Schild Regression. For the most part, the definitive classification of the major drug receptor types and subtypes has been accomplished with selective competitive antagonists. In fact, antagonists are generally more selective for receptor subtypes than are agonists. There may be chemical reasons for this phenomenon if antagonists, generally larger and more flexible molecules and often bearing the chemical structure of agonists with added lipophilic structural groups (24, 465), bind to accessory sites around the agonist binding site of the receptor. This idea, discussed as a "complimentarity principle" by Ariens and coworkers (24) dictates a sharper differentiation of receptor subtypes by antagonists rather than agonists. For larger molecules such as antagonists, variations in accessory sites, as perhaps expected with differences in the membrane constituents in various cells, may be important determinants of binding.

Ideally, the potency of a competitive antagonist depends upon its equilibrium dissociation constant ($K_B$) for the drug receptor, a chemical term governed only by the molecular forces that control the rate of onset and offset of the antagonist to and from the tertiary structural and cognitive components of the drug receptor protein. Therefore the $K_B$, like the $K_I$ for inhibition of a competitive enzyme inhibitor for an enzyme, is a chemical term which hopefully is independent of receptor function, location, and animal species. Considering the importance of reliable estimates of $K_B$ for antagonists it is not surprising that much pharmacological literature is concerned with efforts to make accurate estimates of $K_B$ values.

The first independent scale for antagonist potency with theoretical relevance to equilibrium dissociation constants was devised by Schild (566) and given the name the $pA_2$ scale. Within this nomenclature, the $pA_2$ is an empirical parameter that defines the negative loga-
rhythm of the molar concentration of an antagonist which produces a twofold shift to the right of a concentration-response curve (564, 565).

By using Gaddum's classic formulation for simple competitive antagonism (243, 244):

$$\rho = \frac{1}{1 + \frac{K_A}{[A]} \left(1 + \frac{[B]}{K_B}\right)}$$  \hspace{1cm} (39)

where fractional receptor occupancy ($\rho$) is a function of the molar concentrations of agonist [$A$] and antagonist [$B$] and their respective equilibrium dissociation constants ($K_A$ and $K_B$), Schild derived a useful equation to calculate the $K_B$ of a competitive antagonist (28):

$$\log(dr - 1) = n \cdot \log[B] - \log K_B$$  \hspace{1cm} (40)

where dr refers to the ratio of equiactive concentrations of agonist in the absence and presence of an antagonist [$B$]. The above equation, often referred to as the Schild equation, allows for a convenient estimation of $K_B$ by a linear regression of a series of dose ratios [in the form $\log(dr - 1)$] obtained with a range of concentrations of antagonist (regression upon $\log[B]$). Providing the regression is linear and that the slope is unity ($n = 1$), the intercept is $-\log K_B$ (termed the pKB). A Schild regression slope of unity implies a one-to-one relationship between antagonist and receptor with no substantial cooperative effects. In a comprehensive comparison of antagonist kinetics based on the standard occupation model of drug action and various cooperative models, Colquhoun (143) has shown that the Schild regressions will not differ under a variety of circumstances. However, Sine and Taylor (580A) show that the $K_B$ calculated by Schild analysis could differ appreciably from the antagonist binding constant in systems where the two drug molecules must bind to two cooperatively linked sites to activate a receptor (i.e., the nicotinic receptor on skeletal muscle) if the affinity of the antagonist for the two sites differs substantially. It can be seen from Eq. 40 that the zero value of the ordinate at the pKB is obtained when $dr = 2$ thus the pKB is also the empirical constant pA2. The converse, namely that the pA2 is also the pKB, is very often not true, a fact that has led to periodic confusion in the classification of receptors. The Schild method has two criteria which must be met before the pA2 can be considered to be a representation of the pKB; the regression must be linear and have a slope of unity. In practical terms these criteria are extremely important in experimental pharmacology for two reasons. Firstly, although many drugs which are not competitive antagonists produce parallel displacement of agonist concentration-response curves in a manner identical to competitive antagonists (244), the quantitative relationship between the concentration of drug and degree of shift does not fit simple competitive kinetics. This fact often can be detected by Schild analysis where the slope of the regression will not be unity over a large concentration range. Secondly, the slope and linearity of a Schild regression can be sensitive indicators of nonequilibrium conditions in an isolated tissue. Thus, if a nonlinear Schild regression is obtained in a given isolated tissue with a known competitive antagonist, it would signify deviation from equilibrium either with respect to the concentrations of agonist and antagonist, temporal equilibration or homogeneity of the receptor population. It is worth considering each of these conditions and how they relate to Schild regressions.

### Table 9

Methods to increase tissue sensitivity to agonists

<table>
<thead>
<tr>
<th>Species</th>
<th>Tissue</th>
<th>Receptor*</th>
<th>Method</th>
<th>References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rat</td>
<td>Atria</td>
<td>$\beta$</td>
<td>Chronic propranolol and withdrawal</td>
<td>(623)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\alpha$</td>
<td>Acute thyroxine</td>
<td>(196)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>ACh</td>
<td>Hypothyroid state</td>
<td>(344)</td>
</tr>
<tr>
<td></td>
<td>Aorta</td>
<td>$\beta$</td>
<td>Chronic phenylephrine</td>
<td>(608)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>(mini-pump)</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Aorta</td>
<td>$\beta$</td>
<td>Chronic propranolol and withdrawal</td>
<td>(623)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Starvation</td>
<td>(167)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\beta$</td>
<td>Demedullation</td>
<td>(224)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>$\alpha$</td>
<td>Diet restriction</td>
<td>(600)</td>
</tr>
<tr>
<td>Guinea pig</td>
<td>Atria</td>
<td>$\beta$</td>
<td>Reserpine</td>
<td>(640)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Chronic thyroxine</td>
<td>(382)</td>
</tr>
<tr>
<td>Rabbit</td>
<td>Aorta</td>
<td>$\alpha$</td>
<td>$^{131}$I-Hypothyroidism</td>
<td>(547)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>5-HT</td>
<td>Hyperlipidemia</td>
<td>(711)</td>
</tr>
<tr>
<td></td>
<td>Ear artery</td>
<td>$\alpha$</td>
<td>Denervation</td>
<td>(18)</td>
</tr>
<tr>
<td></td>
<td>Saphenous vein</td>
<td>$\alpha$</td>
<td>Estrogen, progesterone</td>
<td>(545)</td>
</tr>
<tr>
<td></td>
<td>Coronary artery</td>
<td>5-HT</td>
<td>Hyperlipidemia</td>
<td>(711)</td>
</tr>
</tbody>
</table>

* $\beta$, $\beta$-adrenergic; $\alpha$, $\alpha$-adrenergic; ACh, acetylcholine; 5-HT, 5-hydroxytryptamine.
A. SLOPE <1. The first experimental condition to consider is the Schild regression with a slope less than unity either over the complete concentration range or a portion of the antagonist concentrations tested. One of the most common causes of slopes less than unity are agonist uptake processes in isolated tissues. For example, in a tissue with an agonist uptake process, a fraction of the agonist added to the organ bath will not reach the receptors and a steady-state deficit of agonist between organ bath and receptor compartment concentrations of agonist will develop (i.e., see figure 4). Therefore, the control concentration-response curve to the agonist will be shifted to the right of the true curve. Then, if a concentration of antagonist produces conditions such that the concentration-response curve to the agonist is shifted far to the right and large concentrations of agonist, which saturate the uptake process, are required for responses, then uptake ceases to be a consideration for this shifted curve. In terms of the discussion for figure 4, the control curve in region 1 and the shifted curve in regions 2 or 3 of the uptake-concentration relationship. Since uptake removes no appreciable fraction of agonist from the shifted curve, a potentiation of agonist response is effected and the antagonism is reduced by a multiple factor relating to the importance of the uptake process. This reduction of antagonism is reflected in a Schild regression (or portions thereof) with a slope less than unity. The same phenomenon can occur if the competitive antagonist for the receptors also blocks the uptake of agonist at some concentration. Where, along the log[B] axis these effects are observed is determined by the relationship between the concentrations of agonist (and antagonist) and the K_m for uptake and the equilibrium dissociation constants for the receptors. The effects on Schild regressions can be complex, from nonlinear biophase curves to linear parallel shifts to the right. A concise model by Furchgott (232, 239) is useful for the description and prediction of these effects. Thus, the concentration of agonist in the organ bath [A_5] is related to that at the receptor [A_receptor] by the following equation (232):

\[ [A_5] = [A_{receptor}]K_{AU}(1 + [B]/K_B) \]

\[ \times \left[ 1 + \frac{U_m}{k \cdot K_{AU}} \left( 1 + \frac{[A_{receptor}]K_{AU}}{K_B \cdot K_{BU}} + \frac{[B]}{K_B} + \frac{1}{K_{BU}} \right) \right] \]  

where [B] refers to the molar concentration of the antagonist, K_A and K_B the equilibrium dissociation constants for the receptor of the agonist and antagonist, respectively, k the transfer rate constant of the agonist into the receptor compartment, K_{AU} the Michaelis-Menten constant of the agonist for the site of uptake, K_{BU} the equilibrium dissociation constant of the antagonist for the site of uptake, and U_m the maximal rate of uptake. This equation is based on a model which equates the rate of entry of agonist into the receptor compartment by bulk diffusion to the rate of removal of agonist by an uptake process with Michaelis-Menten kinetics. With Eq. 41, given the K_{AU} for an uptake process and equilibrium dissociation constants for the receptors, theoretical Schild regressions may be calculated which show a variety of contours and displacements (for calculated examples see 232, 239, 380, 385, 490). The maximal rates of diffusion and uptake are not required as a prerequisite to the use of this equation since the ratio of these terms can be estimated by the maximal degree of sensitization to the agonist after complete uptake inhibition (see Eq. 10). The conversion of nonlinear into linear Schild regressions by inhibition of agonist uptake processes has been shown in a variety of isolated tissues (103, 104, 131, 232, 239, 336, 380, 385, 410, 426, 463, 490).

B. SLOPE >1. Schild regressions with slopes greater than unity can be produced by inadequate periods of equilibration for the tissue with the antagonist if drug-receptor interaction and not diffusion is the rate-limiting step (369). The theoretical Schild regressions can be calculated by (369):

\[ \log(d_r - 1) = \log[B] - \log K_B \]

\[ + \log \left[ \frac{1 - \exp(-k_2([B]/K_B + 1)t)}{1 + ([(B)/K_B] \exp(-k_2([B]/K_B + 1)t))} \right] \]  

where d_r is the dose ratio at time t, k_2 is the rate of offset of antagonist from the receptor, and K_B is assumed to be k_2/k_1 (k_1 being the rate of onset of antagonist for receptors). Thus, over inadequate equilibration times, the fractional antagonist receptor occupancy (as compared to that at equilibrium) will be greater for higher concentrations and less for lower concentrations (near the pK_B) and a nonlinear Schild regression with portions of slope >1 is predicted. As is evident in Eq. 42, the effect is time-dependent as well as antagonist-concentration dependent thus the concentrations of antagonist over which the slope is greater than unity varies with equilibration time. The potency of antagonists has long been known to be dependent upon equilibration time (230, 247, 369, 506, 525, 564) and demonstration of time-independent pK_B estimates clearly is a prerequisite to the use of antagonists for drug and drug-receptor classification. Other experimental conditions which could produce steep slopes for Schild regressions could involve antagonist induced tissue depression if these effects are...
more prominent at higher rather than lower concentrations of antagonist.

C. SLOPE = 1, BUT SPURIOUS pK_B. If diffusion and not drug receptor interaction is the rate-limiting step in an isolated tissue, then inadequate equilibration times will not affect the slope of the Schild regression but rather will cause it to be shifted to the right of the true Schild regression. The degree of shift is inversely proportional to \( k_{out} \) (the rate of diffusion of the antagonist out of the diffusion barrier) and the equilibration time. The equation to describe these effects is (369):

\[
\log(dr_i - 1) = \log[B] - \log K_B + \log(1 - \exp(-k_{out}t)) \tag{43}
\]

where \( dr_i \) is the dose ratio at time \( t \). Note how in Eq. 43 there is no term containing both \( t \) and \([B]\) therefore no aberration of slope should occur.

Schild regressions may be shifted to the right (with a slope of unity) by injudicious overuse of uptake inhibitors if the uptake inhibitors possess affinity for the drug receptors. For example, use of amitriptyline as an inhibitor of neuronal uptake in the rat anococcygeus muscle produces an increase in the slope of the Schild regression to phenolamine from 0.5, in the absence of uptake inhibition, to 1.0 after inhibition of uptake. However, the regression in the presence of amitriptyline, although linear with a slope not significantly different from unity, is shifted to the right of the correct one by a factor of 50 and yields a spurious pK_B (380). This is because of the significant \( \alpha \)-adrenoceptor blocking properties of amitriptyline (380, 415). The Schild regression for a tissue possessing an agonist uptake process which is partially inhibited by an uptake inhibitor with receptor-blocking properties can be calculated by an equation similar to Furchgott’s (380):

\[
[A_i] = [A_{ib}] \left( 1 + \frac{[B]}{K_B} + \frac{[I]}{K_I} \cdot \frac{1}{\phi} \right)
\]

\[
\times \left[ 1 + \frac{U_m}{k \cdot K_{AU}} \frac{1}{1 + \frac{[A_{ib}]}{K_{AU}} \left( 1 + \frac{[B]}{K_B} + \frac{[I]}{K_I} \cdot \frac{1}{\phi} \right)} \right] \tag{44}
\]

where \( I \) is the uptake inhibitor, \( K_I \) the equilibrium dissociation constant of the inhibitor for the site of uptake, and \( \phi \) the ratio of the equilibrium dissociation constants of the inhibitor for the receptor \((K_{IR})\) and \( K_I \). The other parameters are as for Eq. 41. Theoretical calculations show that the ratio of equilibrium dissociation constants of the uptake inhibitor for the receptor and site of uptake should be 20 or greater to prevent significant error in the estimation of a pK_B. Experimental results indicate that 12.5 is insufficient (380).

Finally, the corroborative nature of the Schild regression slope should be stressed in that a linear Schild regression with a slope of unity is consistent with but not proof of simple competitive antagonism of a homogeneous population of receptors. For example, the physiological antagonism of carbachol induced contractions of guinea pig trachea by \( \beta \)-isoproterenol produces dose ratios which yield a linear Schild regression with a slope of unity (374).

Considering the variety of ways in which a single estimate of the pA_2 can be in error with respect to the true pK_B, receptor classification on the basis of pA_2 values theoretically is unsound. Rather, a pK_B value with an adequate estimation of the slope of the Schild regression is much more preferable since the slope gives a measure of the confidence with which the intercept can be equated to the equilibrium dissociation constant of the antagonist for the receptor.

D. THE “HEMI-EQUILIBRIUM” STATE. There are kinetic conditions under which competitive antagonists shift agonist concentration-response curves to the right but also depress the maximal responses. This is most commonly encountered with persistent (low rate of offset) antagonists and low efficacy agonists. Described by Paton and Waud as a “hemi-equilibrium” state between agonist, antagonist and receptors (506A, 507), the equilibrium of the antagonist is not changed by the presence of the agonist and the agonist equilibrates with only a portion of the total receptor population. Under these conditions, the antagonist behaves as an essentially irreversible blocker and produces insurmountable antagonism. The degree of depression of the maximal response for any given dose ratio is dependent upon the intrinsic efficacy of the agonist. Figure 12 shows the depression of concentration-response curves of guinea pig ileal longitudinal smooth muscle strips to \( n \)-octyltrimethylammonium by hyoscine (527A). An estimate of the K_B of the antagonist can be made with the following equation (507):

\[
\frac{1}{[A]} = \frac{1}{K_A} \cdot \frac{\rho}{(1 - \rho)} + \frac{1}{(1 - \rho)} \cdot \frac{1}{[A']} \tag{45}
\]

where \([A]\) and \([A']\) refer to equiactive concentrations of agonist in the presence and absence of antagonist \((B)\), respectively, and \( K_A \) the equilibrium dissociation constant of the agonist. Therefore, a double reciprocal regression of \(1/[A]\) upon \(1/[A']\) should yield a straight line with a positive intercept. The K_B then can be calculated by:

\[
K_B = \frac{[B]}{(\text{slope} - 1)} \tag{46}
\]

Using Eq. 45, Rang (527A) calculated the K_B for hyoscine with three alkyl-trimethylammonium compounds and found agreement with independent estimates by hyoscine antagonism of methylurmetheide.

This method is most accurate when the dissociation rate constant of the antagonist is much lower than that of agonist. As the rate constant of the antagonist in-
propranolol for
firm amalgam of the equilibrium dissociation constants of agonists. The apparent PKB values would then be an
types with varying affinity for propranolol and the three
explains the data in terms of a mixture of two receptor
pranolol. However, theoretical models, based on occu-
corresponding to the three distinct PKB values for pro-
character this apparent PKB will have depends upon the
increases, relative to that of the agonist, simple competitive
E. RECEPTOR HETEROGENEITY AND ESTIMATIONS
of the pKB. The Schild equation predicts a linear
regression with a slope of unity when a simple competi-
tive antagonist competitively binds to a homogeneous
population of receptors to chemically titrate the number
of free receptors for agonist binding. The resulting pKB
under these circumstances is a constant which reflects
only antagonist receptor interaction and is independent
of the agonist used. However, in practice, there are
isolated tissues where agonist dependent Schild regres-
sions have been obtained and under conditions which
preclude consideration of agonist uptake processes (233,
234).
Figure 13A gives data from Furchgott (235) showing
linear Schild regressions with slopes of unity which yield
agonist dependent pKB values for propranolol in guinea
pig trachea. This is a striking finding since on the surface
it suggests three separate β-adrenoceptors in this tissue
corresponding to the three distinct pKB values for pro-
pranolol. However, theoretical models, based on occup-
ation theory, suggest an alternative hypothesis which
explains the data in terms of a mixture of two receptor
types with varying affinity for propranolol and the three
agonists. The apparent pKB values would then be an
amalgam of the equilibrium dissociation constants of
propranolol for β1- and β2-adrenoceptors. The bias in
terms of how much β1- and how much β2-adrenoceptor
character this apparent pKB will have depends upon the
relative amounts of stimuli the various agonists generate
from each receptor type. The apparent pKB values out-
wardly satisfy the requirements of true equilibrium dis-
sociation constants for homogeneous receptors yet are
artifacts of the Schild method.
This problem was first modelled by Furchgott who
calculated responses from two receptors in terms of
classical occupation theory assuming that the stimuli
from each receptor type was additive. Response was
taken to be a rectangular hyperbolic function of total
stimulus (general logistic Eq. 24 where β = 1 and n = 2).
In the calculations, Furchgott assumed that the agonist
had equal intrinsic efficacy for the two receptor types
but that both the agonist and antagonist had different
affinities for the two sites. A biphasic Schild plot was
calculated as shown in figure 13B. Of note here are the
linear portions of the regression illustrating the potential
for the observation of apparently simple kinetics (linear
Schild regression with a slope of unity) in a complex
system. In terms of this model, the factor which deter-
mines whether or not the Schild regression in a tissue
with a heterogeneous receptor population has a slope of
unity or less than unity is the concentration range of
agonist over which the analysis is carried out.
A useful model by Lemoine and Kaumann (417), which
assumes a receptor reserve for both agonists, has been
recently used to calculate theoretical Schild regressions
in two receptor systems. The regressions were calculated
by (417):
\[
log(dr - 1) = \log[B] \\
- \log \left\{ \frac{(aQK_{Q} + aRK_{R})[B] + K_{Q}K_{R}}{[B] + \sigma_{Q}K_{Q} + \sigma_{R}K_{R}} \right\}
\]
where \( \sigma_{Q} \) and \( \sigma_{R} \) referred to the fractional stimuli elicited
by the agonist from receptor types \( Q \) and \( R \), respectively,
and \( K_{Q} \) and \( K_{R} \) referred to the respective equilibrium
dissociation constants of the antagonist for each receptor
subtype. Figure 14 illustrates clearly the linear character
of portions of Schild regressions calculated for tissues
with heterogeneous receptor populations. The calculated
regression provided an acceptable fit to data from guinea
pig trachea (417).
Just as different Schild regressions can be obtained
for one antagonist in a tissue bearing a heterogeneous
receptor population with different agonists, so too could
different Schild regressions be obtained for the same
agonist-antagonist pair in different tissues if those tis-
sues have different relative proportions of two receptor
types. Assuming a population of tissues with two receptor
subtypes, \( R_{1} \) and \( R_{2} \), the stimulus from \( R_{1} \) produced by
an agonist \([A]\) in the presence of an antagonist \([B]\)
would be:
\[
S_{1} = \frac{\varepsilon_{1} \cdot [R_{1}]}{1 + \frac{K_{1}}{[A] \left( 1 + \frac{|B|}{K_{B1}} \right)}}
\]
where \( K_1 \) and \( K_{B1} \) refer to the equilibrium dissociation constants of the agonist and antagonist for the receptor, respectively. Likewise for the stimulus from \( R_2 \):

\[
S_2 = \frac{e_2 \cdot [R_2]}{1 + \frac{K_2}{[A]} \left(1 + \frac{[B]}{K_{B2}}\right)}. \tag{49}
\]

Using these equations, Schild regressions for systems with various relative proportions of \([R_1]\) and \([R_2]\) were calculated. A modification of the additive stimulus assumption used by Furchgott (236) and Lemoine and Kaumann (417) was introduced into this calculation to allow for unequal coupling of receptor populations. Thus, secondary stimuli \( S'_1 \) and \( S'_2 \) products of saturable functions of the primary stimuli, were considered additive. This is formally identical to the subsequent stimuli hypothesis outlined by Mackay (434) where the secondary stimulus \( S_0 \) is related to the primary stimulus \( S_n \) by:

\[
S_0 = \frac{S_n}{aS_n + b} \tag{50}
\]

where \( a \) and \( b \) are chain constants.

In these calculations, the secondary stimulus \( S'_1 = f_1 (S_1) \) and \( S'_2 = f_2 (S_2) \) where \( f_1 \) and \( f_2 \) need not be identical. The function chosen for these calculations was the general logistic with fitting constants \( \beta_1 \) and \( \beta_2 \) (Eq. 24). Note that Eq. 50 is a special case of the general logistic function \( (n = a = 1, b = \beta) \). The response was considered to be a general logistic function (fitting constant \( \beta_0 \) of the arithmetic sum of \( S'_1 \) and \( S'_2 \). It should be noted that these mathematical expedients do not affect the outcome of predictions for the two receptor models on Schild regressions but simply build in the concepts of a nonlinear function between receptor occupancy and tissue response and unequal coupling of the two receptor populations. There is no reason a priori for two receptor populations to be coupled with equal efficiency such that there is a direct correspondence between the relative numbers of the two receptor populations and the relative stimulus derived from each.

With this model, theoretical Schild regressions for an agonist with equal efficacy and affinity for \( R_1 \) and \( R_2 \) and an antagonist with 100 times the affinity for \( R_1 \) as \( R_2 \) were calculated in a range of tissues with varying relative proportions of \( R_1 \) and \( R_2 \) ([\( R_1 \]/[\( R_2 \] = 1000 to 0.01). For illustrative purposes, equal coupling of \( R_1 \) and \( R_2 \) for the response mechanism was assumed for this example but it should be stressed that the relationship between the observed \( pA_2 \) and the ratio of \([R_1]/[R_2] \) is a direct result of this assumption and therefore is not meaningful. However, there is value in this calculation since it shows the relationship between the location of the Schild regression.
and the slope as it relates to receptor heterogeneity. This relationship is not dependent upon the relative affinity and efficacy of the drugs for the receptor types or the relative efficiency of coupling of the receptor types. Figure 15A shows the effects of changing relative receptor number on the Schild regression. The designated $K_B$ for $R_1$ is 10 nM and for $R_2$ is 1 $\mu$M ($K_{B1}/K_{B2} = 100$). At the extremes of nearly homogeneous populations of $R_1 (\{R_1\}/\{R_2\} = 1000)$ or $R_2 (\{R_1\}/\{R_2\} = 0.01)$, the regressions are linear with slopes of unity and yield the correct $pK_B$ for the respective receptor types. However, at intermediate mixtures of receptor types, the regressions are displaced with a linear portion generally at log $(dr - 1) > 1$ and a nonlinear segment near the $pA_2$. Figure 15B shows the slopes of the regressions at various ratios of
receptor types. The calculations indicate that while slopes less than unity could be expected at dose ratios from 2 to 30, larger dose ratios yield regressions in which nonlinearity would be difficult to detect. This is in agreement with numerous published Schild regressions in tissues with heterogeneous receptor populations which have slopes of unity (235,485–487,554,555,558). In terms of satisfying the conditions for simple competitive antagonism, a linear Schild regression with a slope of unity would constitute evidence for the intercept to be considered the pK_B. However, as the foregoing analysis indicates, the intercept would reflect an artifactual pK_B value as a weighted average the pK_B for two receptor types in a tissue containing two types of receptor. Figure 15C shows the influence of relative efficacy of the agonist for two receptors on the observed pK_B of Schild regressions in tissues with varying relative amounts of the two receptor types ($K_{B2}/K_{B1} = 100$). The actual value of the pK_B equated to a given ratio of $[R_1]/[R_2]$ depends upon the coupling of the two receptor populations to the tissue response machinery. The calculations in Figure 15C assumed equal coupling.

There are an increasing number of tissues found to have heterogeneous receptor subpopulations as measured by binding studies (97,305,318,457–459,466,471,556). In some cases the receptor heterogeneity found in binding studies can be corroborated in pharmacological studies with isolated tissues, but in others the heterogeneous receptor subpopulations found by binding are not reflected in tissue responses. For example, in the rabbit uterus binding studies showed that $\alpha_1$- and $\alpha_2$-adrenoceptors were coexistent but responses appeared to be mediated only by the $\alpha_1$-adrenoceptors (318).

Pharmacological experiments in isolated tissues indicate a heterogeneous population of $\beta$-adrenoceptors in guinea pig trachea (233–235,240,241,485), cat heart (117,118), and rat adipose tissue (298). Heterogeneous populations of postsynaptic $\alpha$-adrenoceptors may be present in dog basilar artery (558), rat perfused hind quarters (657), dog saphenous vein (148,607), and rat tail artery (312).

The foregoing theoretical analyses suggest that a spectrum of apparently linear Schild regressions could be expected from a range of tissues with varying relative quantities of two discrete receptor types which subserves the same type of response. Alternatively, if accessory binding sites around the active site of the receptor are required for antagonist binding, then a continuous spectrum of binding constants might be expected with differing lipid constituents of biological membrane which could, in turn, affect the conformation of the receptor protein. This scheme of “multiple environment” as opposed to “multiple receptors” has been proposed to explain the profusion of opiate receptors (465). This hypothesis would predict a grey area of binding constants between two extremes which would reflect a range of pK_B values for a spectrum of receptor configurations. This concept differs from the discrete two-receptor idea which would predict chimerical or artifactual pK_B values within this grey area.

2. Other Methods to Calculate $pK_B$. The Schild method is by far the most ubiquitous in pharmacology for the measurement of equilibrium dissociation constants of competitive antagonists (374). Useful guidelines for statistical manipulations with this method have been given by MacKay (432) and Tallarida and coworkers (613).

There are other methods available for the calculation of pK_B values. A method utilizing the “L transformation” has been proposed by MacKay and Wheeler (435). A method with theoretical advantages over the Schild regression is one utilizing the “Clark plot” (603,604). Brazenor and Angus (92) have shown that estimates of the pK_B using the Clark plot and Schild regression can differ significantly. A method based on an equation by Ariens termed the “dynamic approach” has been proposed by Amidon and Buckner (10). In this method, a fixed ratio $Q$ of agonist $[A']$ and antagonist $[B]$ are physically mixed and the mixture used to obtain a concentration-response curve in a tissue. This curve is compared to a control curve to the agonist alone $[A]$ and equiactive agonist concentrations are equated with the following relationship:

$$\frac{1}{[A]} = \frac{Q}{K_B} + \frac{1}{[A']}$$

Thus, the reciprocal of the intercept of a double reciprocal plot of $1/[A]$ versus $1/[A'] \times Q$ yields an estimate of the $K_B$.

VI. Operational Concepts in Receptor Classification

The basis of drug and drug receptor classification is the unequivocal measurement and comparison of parameters which depend only upon drug and receptor interaction. The philosophical step from such data to the postulate of a new receptor type or agonist/antagonist selectivity is, in the end, still subjective (432). The soundest approach would appear to be to eliminate as many obfuscating factors as possible that make organ selectivity appear to be due to receptor selectivity (373,376) and quantitatively compare, with appropriate statistical procedures, the drug receptor parameters. A popular guideline set forth by Furchgott (232) for distinguishing receptors with competitive antagonists is the postulate that a threefold difference in $K_B$ values constitutes evidence for differences in receptors. Another possibility is the use of analysis of covariance of regression lines (591) to compare linear regression lines with respect to slope and elevation (385). Thus, all of the data in Schild regressions could be utilized instead of only the intercept. This procedure lends itself to any method that utilizes linear regressions.
VII. Relevance to New Drugs

Isolated tissues are widely used in industry for the finding of new therapeutic entities for the treatment of diseases in man. A valuable byproduct of this process is the discovery of selective drugs for the classification of drug receptors (445, 575–577). An effective, if labor intensive, approach towards this end is the random screening of many chemical compounds in appropriate in vitro test systems. In this context, the term random refers to the a priori lack of rationale for the choice of chemical to be tested; this opens the doors to the finding of a novel drug (445). The methodological concepts which refer to the proper preservation of tissue viability and caveats to universal ascription of drug selectivity observed in a given tissue to all tissues have relevance to these screening procedures. However, some theoretical concepts under the vague heading of receptor theory may be helpful in the search for new drugs. Intuitively, it might be supposed that a screening program should be targeted to the finding of the most active and selective drug possible but there may be exceptions to both of these criteria.

Firstly, the most potent agonist may not be the most useful if the potency is related mainly to a high efficacy rather than a high affinity. As shown in figure 10B, drugs of high affinity but low efficacy are much more susceptible to the efficiency of receptor coupling than are drugs of high efficacy. Support for this idea can be found in the wide range of agonist activities of prenalterol, a \( \beta \)-adrenoceptor agonist of low efficacy in different tissues (figure 12B). Therefore, organ selectivity in vivo may be better achieved by choosing the agonist of lower efficacy.

In the early formulations of receptor theory, Clark and Raventos (134) distinguished "... the capacity to bind and the capacity to excite...". There are numerous studies that show the structure-activity relationships for affinity and efficacy to be quite different (553–555, 599). Figure 16 shows the separate structure-activity relationships of some drugs for \( \alpha \)-adrenoceptors and highlights the independence of the properties of affinity and efficacy in drugs. For example, synephrine (4-OH, figure 16A) and 3-hydroxytolazoline (3-OH, figure 16B) show comparable activity in guinea pig aorta (555) and it would be predicted that these agonists would be equiactive full agonists in tissues with large receptor reserves (i.e., a potency ratio of 1.88 by Eq. 23). However, the agonist profiles of these two agonists would be very different (i.e., synephrine \( \gg \) 3-hydroxytolazoline) in tissues with little receptor reserve. This would be due to the differences in efficacy of the two drugs. Without knowledge of the relative efficacy of these drugs, the screening results on different tissues could be misleading. For example, if screened on tissues with large receptor reserves, the drugs would be assumed to be equiactive with a corresponding assumption that this profile would be true in vivo. Alternatively, if screened on a tissue with a low receptor reserve, the disparate agonist profiles might suggest artifactual receptor selective effects. Knowledge of both efficacy and affinity could be useful in the predictions of agonist effects in man.

Secondly, the concept of high selectivity may be overstressed as well. A screening program targeted to the finding of a drug with a single unique action presupposes the existence of a unique and convenient hitherto undetected receptor or mechanism that will subserve the desired activity. This is, of course, possible but there are elements of wishful thinking in this approach. Another possibility would be the conscious design of two properties within one molecule to produce a drug which, when interacting with organs possessing the two mechanisms with which the drug has activity, produces a selective effect. The selectivity would stem from the varying relative importance the two mechanisms may have in different organs. For example, metanephrine is an inhibitor of the extraneuronal uptake of catecholamines (108) and also is a \( \beta \)-adrenoceptor blocking agent (367, 371). Since the former mechanism sensitizes some tissues to catecholamines and the latter mechanism produces dextral displacement of concentration-response curves to catecholamines, there is a potential for self cancellation. However, diffusional and uptake characteristics of different tissues make extraneuronal uptake of catecholamines (uptake\(_2\)) of varying importance. For example, inhibition of uptake\(_2\) produces no significant sensitization of guinea pig atria (706) but a 5- to 30-fold sensitization of guinea pig trachea (367). Thus metanephrine produces organ selective \( \beta \)-blockade in these tissues; 1 mM metanephrine produces a dose ratio of 3 in guinea pig trachea and 25 in guinea pig atria.

Two activities in one molecule may be critical to the selectivity or overall activity of that molecule in vivo. For example, it is probable that the antihypertensive activity of labetalol relates to the combined \( \alpha \)- and \( \beta \)-adrenoceptor blocking properties of the molecule. The weak partial agonist activity of dobutamine for \( \alpha \)-adrenoceptors coupled with stronger \( \beta \)-adrenoceptor agonist activity may be critical to the selective inotropy observed with this drug in vivo (370).

The elucidation of these mechanisms may be important to the process of finding new drugs. It may be more beneficial for a medicinal chemist to know that a given molecule is selective in vivo because of a combination of activities as opposed to the presumption that it stimulates some hitherto unknown new receptor. Also, the design of drugs with two or more activities increases the chemical starting points for a medicinal chemist in the design of new molecules.

There are indications that combining two properties in one molecule may be useful. Baldwin and coworkers (35) term this the "symbiotic approach" and have used the idea to successfully produce a vasodilator-\( \beta \)-blocking drug. Unfortunately, the full utility of this agent could not be elucidated because of observed teratogenicity.
FIG. 16. Structure-activity relationships for efficacy and affinity of α-adrenoceptor agonists. pKₐ equals the negative logarithm of the equilibrium dissociation constant of the agonist for the receptor. Abscissae for part C: Naphazoline (NAPH), clonidine (CLON), tenaphtoxaline (TEN), 2-(phenylimino)-imidazoline (PI), tetrahydrozoline (TET), tolazoline (TOL), xylometazoline (XYLD), phenylephrine (PE), (3,4-dihydroxyphenylamino)-2-imidazoline (DPI), and oxymetazoline (OXY). Data for parts A and B (guinea pig aorta) from Ruffolo and Waddell (555) and for part C (rat aorta) from Ruffolo et al. (553), reprinted with permission.

Acknowledgments. I wish to especially thank Suzanne Johnson for invaluable assistance in the preparation of this manuscript.

REFERENCES


DRUGS AND DRUG RECEPTORS IN ISOLATED TISSUES


133. CHI, T. H.: Age-dependent changes in the myocardial adenylate cyclase of...
DRUGS AND DRUG RECEPTORS IN ISOLATED TISSUES

213


303. HAZA, J.: Correlation between disioppyflourphosphates (DFP) inhibition of cholinesterase (CHE) of intact rat phrenic nerve-diaphragm and...


367. KAUW, A. M.: Yohimbine and rauwolcine inhibit 5-hydroxytryptamine-


null


